

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION**

In re:

IMPEL PHARMACEUTICALS, INC., *et al.*¹

Debtors.

Chapter 11

Case No. 23-80016 (SGJ)

(Jointly Administered)

**STATEMENT OF FINANCIAL AFFAIRS OF
DEBTOR IMPEL PHARMACEUTICALS, INC. (CASE NO. 23-80016)**

¹ The Debtors in this chapter 11 case, together with the last four digits of the Debtor's federal tax identification number, are: Impel Pharmaceuticals Inc. (8238); and Impel NeuroPharma Australia Pty Ltd (N/A). The Debtors' service address is 201 Elliot Avenue West, Suite 260, Seattle, WA 98119.

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION**

In re:

IMPEL PHARMACEUTICALS, INC., *et al.*¹

Debtors.

Chapter 11

Case No. 23-80016 (SGJ)

(Jointly Administered)

**GLOBAL NOTES AND STATEMENT OF LIMITATIONS,
METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTORS' SCHEDULES
OF ASSETS AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS**

On December 19, 2023 (the “Petition Date”), Impel Pharmaceuticals, Inc. and its affiliated debtor in the above-captioned chapter 11 cases (each a “Debtor” and, collectively, the “Debtors”) commenced voluntary cases (the “Chapter 11 Cases”) under chapter 11 of title 11, United States Code, §§ 101 *et seq.* (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Northern District of Texas (the “Court”).

The Debtors continue to operate their businesses and manage their properties as debtors and debtors in possession, pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. The Chapter 11 Cases have been consolidated for procedural purposes only and are being jointly administered under case number 23-80016 (SGJ).

The Schedules of Assets and Liabilities (the “Schedules”) and Statements of Financial Affairs (the “Statements”) were prepared pursuant to section 521 of the Bankruptcy Code and Rule 1007 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”) by management of the Debtors with unaudited information available as of the Petition Date.

These *Global Notes and Statement of Limitations, Methodology, and Disclaimers Regarding the Debtors' Schedules and Statements of Financial Affairs* (the “Global Notes”) are incorporated by reference in, and comprise an integral part of, each Debtor’s respective Schedules and Statements, and should be referred to and considered in connection with any review of the Schedules and Statements.

In preparing the Schedules and Statements, the Debtors relied on financial data derived from their books and records that was available at the time of such preparation. The Debtors, and their agents, attorneys, and advisors do not guarantee or warrant the accuracy or completeness of the data that is provided herein, and shall not be liable for any loss or injury arising out of or caused

¹ The Debtors in this chapter 11 case, together with the last four digits of the Debtor’s federal tax identification number, are: Impel Pharmaceuticals Inc. (8238); and Impel NeuroPharma Australia Pty Ltd (N/A). The Debtors’ service address is 201 Elliot Avenue West, Suite 260, Seattle, WA 98119.

in whole or in part by the acts, errors, or omissions, whether negligent or otherwise, in procuring, compiling, collecting, interpreting, reporting, communicating, or delivering the information contained herein. While reasonable efforts have been made to provide accurate and complete information herein, inadvertent errors or omissions may exist. The Debtors reserve their rights to amend and supplement the Schedules and Statements as may be necessary or appropriate. For the avoidance of doubt, the Debtors and their agents, attorneys, and advisors expressly do not undertake any obligation to update, modify, revise, or re-categorize the information provided herein, or to notify any third party should the information be updated, modified, revised, or re-categorized, except as required by applicable law. In no event shall the Debtors, or their agents, attorneys, and advisors, be liable to any third party for any direct, indirect, incidental, consequential, or special damages (including, but not limited to, damages arising from the disallowance of a potential claim against the Debtors or damages to business reputation, lost business, or lost profits), whether foreseeable or not and however caused, even if the Debtors or their agents, attorneys, or advisors are advised of the possibility of such damages.

Given, among other things, the uncertainty surrounding the valuation and nature of certain assets and liabilities, to the extent that a Debtor shows more assets than liabilities, this is not an admission that such Debtor was solvent on the Petition Date (as defined below) or at any time prior to the Petition Date. Likewise, to the extent that a Debtor shows more liabilities than assets, it is not an admission that such Debtor was insolvent on the Petition Date or any time prior to the Petition Date.

Brandon Smith has signed each set of the Schedules and Statements. Mr. Smith serves as the Chief Restructuring Officer (“CRO”) of the Debtors, and he is an authorized signatory for each of the Debtors in these chapter 11 cases. In reviewing and signing the Schedules and Statements, Mr. Smith has necessarily relied upon the efforts, statements, advice, and representations of the Debtors and their advisors. Mr. Smith has not (and could not have) personally verified the accuracy of each such statement and representation, including statements and representations concerning amounts owed to creditors, classification of such amounts, and creditor addresses.

Global Notes and Overview of Methodology

1. **Impel NeuroPharma Australia Pty Ltd.** Impel NeuroPharma Australia Pty Ltd (“Impel Australia”) is a wholly-owned subsidiary of Impel Pharmaceuticals Inc. (“Impel”). Impel Australia had no operations other than tax filings and bookkeeping related to its two bank accounts in the year prior to the Petition Date. Impel Australia has no sales receipts. All vendors supporting its bookkeeping and tax filings are paid by Impel. Accordingly, the Debtors have reported the only assets owned by Impel Australia, which include one IOLTA deposit and two bank accounts. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate.

2. **Reservations and Limitations.** Reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements; however, as noted above, inadvertent errors or omissions may exist. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate. Nothing contained in the Schedules and Statements constitutes a waiver of any of the Debtors’ rights or an admission of any kind with respect to these chapter 11 cases, including, but not limited to, any rights or claims of the Debtors

against any third party or issues involving substantive consolidation, equitable subordination, or defenses or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code or any other relevant applicable bankruptcy or non-bankruptcy laws to recover assets or avoid transfers. Any specific reservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this paragraph.

- (a) **No Admission.** Nothing contained in the Schedules and Statements is intended or should be construed as an admission or stipulation of the validity of any claim against the Debtors, any assertion made therein or herein, or a waiver of the Debtors' rights to dispute any claim or assert any cause of action or defense against any party.
- (b) **Recharacterization.** Notwithstanding that the Debtors have made reasonable efforts to correctly characterize, classify, categorize, or designate certain claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and Statements, the Debtors nonetheless may have improperly characterized, classified, categorized, or designated certain items. The Debtors reserve all rights to recharacterize, reclassify, recategorize, or redesignate items reported in the Schedules and Statements at a later time as is necessary and appropriate, including, without limitation, whether contracts or leases listed herein were deemed executory or unexpired as of the Petition Date and remain executory and unexpired post-petition. Disclosure of information in one or more Schedules, Statements, or one or more exhibits or attachments thereto, even if incorrectly placed, shall be deemed to be disclosed in the correct Schedules, Statements, exhibits, or attachments.
- (c) **Classifications.** Listing (i) a claim on Schedule D as "secured," (ii) a claim on Schedule E/F as "priority" or "unsecured," or (iii) a contract on Schedule G as "executory" or "unexpired" does not constitute an admission by the Debtors of the legal rights of the claimant or contract counterparty, or a waiver of the Debtors' rights to recharacterize or reclassify such claim or contract or to setoff such claim.
- (d) **Claims Description.** Any failure to designate a claim on the Debtors' Schedules and Statements as "disputed," "contingent," or "unliquidated" does not constitute an admission by the Debtors that such amount is not "disputed," "contingent," or "unliquidated." Each Debtor reserves all rights to dispute, or assert offsets or defenses to, any claim reflected on its respective Schedules and Statements on any grounds, including, without limitation, liability, or classification, or to otherwise subsequently designate such claims as "disputed," "contingent," or "unliquidated" or object to the extent, validity, enforceability, or priority of any claim. Moreover, listing a claim does not constitute an admission of liability by the Debtors against which the claim is listed or by any of the Debtors. The Debtors reserve all rights to amend their Schedules and Statements as necessary and appropriate, including, but not limited to, with respect to claim description and designation.
- (e) **Estimates and Assumptions.** The preparation of the Schedules and Statements required the Debtors to make reasonable estimates and assumptions with respect to

the reported amounts of assets and liabilities, the amount of contingent assets and contingent liabilities on the Schedules and Statements, and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ from such estimates.

- (f) **Causes of Action.** Despite reasonable efforts, the Debtors may not have identified all current and potential causes of action the Debtors may have against third parties in their respective Schedules and Statements, including, without limitation, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant bankruptcy and non-bankruptcy laws to recover assets. The Debtors reserve all rights with respect to any causes of action, and nothing in these Global Notes or the Schedules and Statements should be construed as a waiver of any such causes of action.
- (g) **Intellectual Property Rights.** Exclusion of certain intellectual property from the Schedules and Statements should not be construed as an admission that such intellectual property rights have been abandoned, have been terminated or otherwise expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property rights in the Schedules and Statements should not be construed as an admission that such intellectual property rights have not been abandoned, have not been terminated or otherwise expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction.
- (h) **Executory Contracts and Unexpired Leases.** Although the Debtors made diligent efforts to identify contracts and unexpired leases as executory within the scope of section 365 of the Bankruptcy Code and to attribute an executory contract to its rightful Debtors, in certain instances, the Debtors may have inadvertently failed to do so due to the complexity and size of the Debtors' businesses. Accordingly, the Debtors reserve all of their rights with respect to the inclusion or exclusion of executory contracts and unexpired leases, as well as the named parties to any and all executory contracts and unexpired leases, including the right to amend Schedule G at any time during the pendency of these chapter 11 cases.
- (i) **Insiders.** In the circumstance where the Schedules and Statements require information regarding "insiders," the Debtors have included information with respect to certain individuals who served as officers and directors, as the case may be, during the relevant time periods. Such individuals may no longer serve in such capacities.

The listing or omission of a party as an insider for purposes of the Schedules and Statements is not intended to be, nor should it be, construed as an admission of any fact, right, claim, or defense and all such rights, claims, and defenses are hereby expressly reserved. Information regarding the individuals listed as insiders in the Schedules and Statements has been included for informational purposes only and such information may not be used for: (i) the purposes of determining (A) control

of the Debtors; (B) the extent to which any individual exercised management responsibilities or functions; (C) corporate decision-making authority over the Debtors; or (D) whether such individual could successfully argue that he or she is not an insider under applicable law, including the Bankruptcy Code and federal securities laws, or with respect to any theories of liability or (ii) any other purpose.

3. **Description of Cases and “As Of” Information Date.** On December 19, 2023 (the “Petition Date”), each of the Debtors filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the Court. The Debtors continue to operate their business. The information provided herein, except as otherwise noted, is reported as of the Petition Date of each respective Debtor, as appropriate.

4. **Methodology.**

- (a) **Basis of Presentation.** The Schedules and Statements do not purport to represent financial statements prepared in accordance with Generally Accepted Accounting Principles in the United States (“GAAP”) nor are they intended to be fully reconciled to the financial statements of each Debtor. The Schedules and Statements contain unaudited information that is subject to further review and potential adjustment. The Schedules and Statements reflect the Debtors’ reasonable efforts to report the assets and liabilities of each Debtor on an unconsolidated basis.
- (b) **Duplication.** Certain of the Debtors’ assets, liabilities, and prepetition payments may properly be disclosed in multiple parts of the Statements and Schedules. To the extent these disclosures would be duplicative, the Debtors have endeavored to only list such assets, liabilities, and prepetition payments once.
- (c) **Net Book Value.** In certain instances, current market valuations for individual items of property and other assets are neither maintained by, nor readily available to the Debtors. Accordingly, unless otherwise indicated, the Debtors’ Schedules and Statements reflect net book values as of the Petition Date. Market values may vary, in some instances, materially, from net book values. The Debtors believe that it would be an inefficient use of estate assets for the Debtors to obtain the current market values of their property. Accordingly, the Debtors have indicated in the Schedules and Statements that the market values of certain assets and liabilities are undetermined. Also, assets that have been fully depreciated or that were expensed for accounting purposes either do not appear in these Schedules and Statements, or are listed with a zero-dollar value, as such assets have no net book value. The omission of an asset from the Schedules and Statements does not constitute a representation regarding the ownership of such asset, and any such omission does not constitute a waiver of any rights of the Debtors with respect to such asset.
- (d) **Undetermined Amounts.** The description of an amount as “unknown,” “TBD,” or “undetermined” is not intended to reflect upon the materiality of such amount.

- (e) **Unliquidated Amounts.** Amounts that could not be fairly quantified by the Debtors are scheduled as “unliquidated.”
- (f) **Totals.** All totals that are included in the Schedules and Statements represent totals of all known amounts. To the extent there are unknown or undetermined amounts, the actual total may be different from the listed total.
- (g) **Paid Claims.** The Debtors have authority to pay certain outstanding prepetition payables pursuant to various orders entered by the Court. The Debtors scheduled such amounts as of the Petition Date and noted such amounts contingent. To the extent the Debtors later pay any amount of the claims listed in the Schedules and Statements pursuant to any orders entered by the Court, the Debtors reserve all rights to amend or supplement the Schedules and Statements or to take other action, such as filing claims objections, as is necessary and appropriate to avoid overpayment or duplicate payments for liabilities. Nothing contained herein should be deemed to alter the rights of any party in interest to contest a payment made pursuant to an order of the Court where such order preserves the right to contest.
- (h) **Liens.** The inventories, property, and equipment listed in the Schedules and Statements are presented without consideration of any liens.
- (i) **Currency.** Unless otherwise indicated, all amounts are reflected in U.S. dollars. Some bank accounts in Impel NeuroPharma Australia Pty Ltd may be held in Australian Dollar (“AUD”) but converted to the U.S. Dollar equivalent as of the Petition Date.
- (j) **Liabilities.** The Debtors have sought to allocate liabilities between the prepetition and postpetition periods based on the information and research conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available and further research is conducted, the allocation of liabilities between the prepetition and postpetition periods may change. The Debtors reserve the right to amend the Schedules and Statements as they deem appropriate in this and all other regards.
- (k) **Excluded Assets and Liabilities.** The Debtors have excluded certain categories of assets and liabilities from the Schedules and Statements, including, but not limited to: certain deferred charges, right-of-use asset and related liabilities, reserves recorded only for purposes of complying with the requirements of GAAP, and deferred tax assets, deferred tax liabilities, and intangible assets. In addition, certain accrued tax benefits from net operating losses that could offset future earnings have been recorded as undetermined. The Debtors have also excluded rejection damage claims of counterparties to executory contracts and unexpired leases that may or may not be rejected, to the extent such damage claims exist. Other immaterial assets and liabilities may also have been excluded.
- (l) **Credits and Adjustments.** The claims of individual creditors for, among other things, goods, products, services, or taxes are listed as the amounts entered on the

Debtors' books and records and may either (i) not reflect credits, allowances, or other adjustments due from such creditors to the Debtors or (ii) be net of accrued credits, allowances, or other adjustments that are actually owed by a creditor to the Debtors on a postpetition basis on account of such credits, allowances, or other adjustments earned from prepetition payments and critical vendor payments, if applicable. The Debtors reserve all of their rights with regard to such credits, allowances, or other adjustments, including, but not limited to, the right to modify the Schedules, assert claims objections and/or setoffs with respect to the same, or apply such allowances in the ordinary course of business on a postpetition basis.

- (m) **Setoffs.** The Debtors may periodically incur setoffs and net payments in the ordinary course of business. Such setoffs and nettings may occur due to a variety of transactions or disputes. Although such setoffs and other similar rights may have been accounted for when scheduling certain amounts, these ordinary course setoffs are not independently accounted for, and as such, are or may be excluded from the Debtors' Schedules and Statements. The Debtors reserve all rights to challenge any setoff and/or recoupment rights that may be asserted.
5. **Global Notes Control.** These Global Notes pertain to and comprise an integral part of each of the Schedules and Statements and should be referenced in connection with any review thereof. In the event that the Schedules and Statements conflict with these Global Notes, these Global Notes shall control.
6. **Specific Schedules Disclosures.**
- (a) **Schedules Summary.** Except as otherwise noted, the asset totals represent amounts as of the Petition Date and liability information provided herein represents the Debtors' liabilities as of the Petition Date.
 - (b) **Schedule A/B, Part 4 – Investments; Non-Publicly Traded Stock and Interests in Incorporated and Unincorporated Businesses, including any Interest in an LLC, Partnership, or Joint Venture.** Ownership interests in subsidiaries have been listed in Schedule A/B, Part 4, as undetermined amounts on account of the fact that the fair market value of such ownership is dependent on numerous variables and factors, and may differ significantly from their net book value.
 - (c) **Schedule A/B, Part 5 – Inventory.** The Debtors' product has a 12-month shelf life. As such the Debtors' customers, specialty pharmacies among others, monitor the production dates of all inventory to be sold to patients. All inventory is held and managed by third parties. The work in progress inventory, listed as SPEC, DHE Mesylate Form, has a net book value of \$0.00. The cost of this inventory was approximately \$765,000 but it has expired and has been fully reserved for booking keeping purposes. As such, the Debtors will need to find a way to dispose of it.
 - (d) **Schedule A/B, Part 7 – Office furniture, fixtures, and equipment; and collectibles.** The Debtors have used book values as of November 30, 2023 for reporting office furniture, fixtures, and equipment. There have been no valuations

on any of such assets. These amounts may include leasehold improvements. The Debtors reserve all of their rights to re-categorize and/or re-characterize such asset holdings to the extent the Debtors determine that such holdings were improperly listed.

- (e) **Schedule A/B, Part 8 – Machinery, equipment, and vehicles.** The Debtors lease certain vehicles for their sales team from a third party. The leases have various expiration dates and monthly payment amounts, and are not owned by the Debtors. Under the lease agreement, the Debtors may return vehicles prior to the expiration date, which could result in a gain/loss depending on the final terms of the agreement. The Debtors have not completed an analysis regarding the gain/loss on the current vehicle fleet.
- (f) **Schedule A/B, Part 9 – Real Property.** The Debtors lease all of their real properties and, as such, the properties' value have been marked as undetermined. Furthermore, certain of the property leases reflected on Schedule A/B 55 may contain renewal options, guarantees of payment, options to purchase, rights of first refusal, rights to lease additional lands, and other miscellaneous rights. Such rights, powers, duties, and obligations are not separately set forth on Schedule A/B 55. The Debtors hereby expressly reserve the right to assert that any instrument listed on Schedule A/B 55 is an executory contract or unexpired lease within the meaning of section 365 of the Bankruptcy Code. The Debtors reserve all of their rights, claims, and causes of action with respect to claims associated with any contracts and agreements listed on Schedule A/B 55, including their right to dispute or challenge the characterization or the structure of any transaction, document, or instrument, including any intercompany agreement.
- (g) **Schedule A/B, Part 10 – Intangibles and Intellectual Property.** The Company may have certain social media accounts that they own but currently do not have access due to reduction in their workforce. The social media accounts have not been listed.
- (h) **Schedule A/B, Part 11 – All Other Assets.** The Debtors have incurred significant net operating losses (“NOLs” and R&D Credits (together, the “Tax Attributes”) since their inception. As of December 31, 2022, the Debtors have generated federal NOLs of \$271.3 million. The Debtors also has \$153.4 million of state NOLs and \$8.4 million of R&D Credits. Further, the Debtors estimate that they may generate additional Tax Attributes in the 2023 tax year. Such Tax Attributes have not been valued as of the Petition Date and may be restricted in their use.
- (i) **Schedule D – Creditors Who Have Claims Secured by Property.** The Debtors have made reasonable efforts to report all secured claims against the Debtors on Schedule D based on the Debtors' books and records as of the Petition Date. However, the actual value of claims against the Debtors may vary significantly from the represented liabilities. Parties in interest should not accept that the listed liabilities necessarily reflect the correct amount of any secured creditor's allowed claims or the correct amount of all secured claims. Similarly, parties in interest

should not anticipate that recoveries in these cases will reflect the relationship of the aggregate asset values and aggregate liabilities set forth in the Schedules. Parties in interest should consult their own professionals and advisors with respect to pursuing a claim. Although the Debtors and their professionals have generated financial information and data the Debtors believe to be reasonable, actual liabilities (and assets) may deviate significantly from the Schedules due to certain events that occur throughout these Chapter 11 Cases.

Except as specifically stated herein, lessors of real property and equipment, utility companies, and any other parties which may hold security deposits or other security interests, have not been listed on Schedule D. The Debtors have also not listed on Schedule D any parties whose claims may be secured through rights of setoff, deposits, or advance payments.

Although the Debtors may have scheduled claims of various creditors as secured claims, the Debtors reserve all rights to dispute or challenge the secured nature of any creditor's claim or the characterization of the structure of any transaction or any document or instrument (including, without limitation, any intercompany agreement) related to such creditor's claim (except as otherwise agreed to or stated pursuant to a stipulation, agreed order, or general order entered by the Bankruptcy Court that is or becomes final). The Debtors have not included on Schedule D the claims of any parties that may believe their claims are secured through setoff rights or inchoate statutory lien rights.

The descriptions provided on Schedule D are intended only as a summary. Reference to the applicable loan agreements and related documents is necessary for a complete description of the collateral and the nature, extent, and priority of any liens. Nothing in these Global Notes or in the Schedules and Statements shall be deemed a modification, interpretation, or an acknowledgment of the terms of such agreements or related documents.

(j) Schedule E/F – Creditors Who Have Unsecured Claims.

The Debtors have made reasonable efforts to report all priority and general unsecured claims against the Debtors on Schedule E/F based on the Debtors' books and records as of the Petition Date. However, the actual value of claims against the Debtors may vary significantly from the represented liabilities. Certain claims on E/F may have been satisfied post-petition by the Debtors (including employee wages in the ordinary course) or third parties. Furthermore, accrued interest for some claims may not have been possible to determine. Parties in interest should not accept that the listed liabilities necessarily reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims. Similarly, parties in interest should not anticipate that recoveries in these cases will reflect the relationship of the aggregate asset values and aggregate liabilities set forth in the Schedules. Parties in interest should consult their own professionals and advisors with respect to pursuing a claim. Although the Debtors and their professionals have generated financial information and data the Debtors believe to

be reasonable, actual liabilities (and assets) may deviate significantly from the Schedules due to certain events that occur throughout these Chapter 11 Cases.

The claims listed on Schedule E/F arose or were incurred on various dates. In certain instances, the date on which a claim arose may be unknown or subject to dispute. Although reasonable efforts have been made to determine the date upon which claims listed in Schedule E/F were incurred or arose, updating that date for each claim in Schedule E/F would be unduly burdensome and cost-prohibitive and, therefore, the Debtors have not listed a date for each claim listed on Schedule E/F.

In the ordinary course of business, the Debtors generally receive invoices for goods and services after the delivery of such goods or services. As of the filing of the Schedules and Statements, the Debtors may not have received all invoices for payables, expenses, or liabilities that may have accrued before the Petition Date. Furthermore, payments to vendors and lienholders made subsequent to the filing of these Schedules will not be reflected in these Schedules. The Debtors reserve the right, but are not required, to amend Schedules E/F if they receive such invoices and/or make such payments. The claims of individual creditors are generally listed at the amounts recorded on the Debtors' books and records and may not reflect all credits or allowances due from the creditor. The Debtors reserve all of their rights concerning credits or allowances.

Part 1 - Creditors with Priority Unsecured Claims. The Debtors included certain claims owing to various taxing authorities to which the Debtors may be liable. Certain of the claims may be subject to ongoing audits and the Debtors may otherwise be unable to determine with certainty the amount of such claims. Therefore, for certain claims, the Debtors have listed such claims as disputed, contingent, and unliquidated, pending final resolution of ongoing audits and other outstanding issues. Moreover, the inclusion of any amounts owed to taxing authorities does not constitute an admission by the Debtors of such liability. The Debtors reserve the right to assert that any claim listed on Schedule E/F does not constitute a priority claim under the Bankruptcy Code.

Part 2 - Creditors with Nonpriority Unsecured Claims. The Debtors have used reasonable efforts to report all general unsecured claims against the Debtors in Schedule E/F, Part 2, based upon the Debtors' books and records as of the Petition Date. The Debtors made a reasonable attempt to set forth their unsecured obligations, although the actual amount of claims against the Debtors may vary from those liabilities represented on Schedule E/F, Part 2. The listed liabilities, which have been listed on a gross accounts payable basis, may not reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims.

Schedule E/F, Part 2, reflects certain prepetition amounts owing to counterparties to executory contracts and unexpired leases. Such prepetition amounts, however, may be paid in connection with the assumption or assumption and assignment of an executory contract or unexpired lease. Prepetition amounts that may be paid in

accordance with court orders, are marked as contingent. In addition, Schedule E/F, Part 2, does not include claims that may arise in connection with the rejection of any executory contracts and unexpired leases, if any, that may be or have been rejected.

- (k) **Schedule G – Executory Contracts and Unexpired Leases.** The Debtors hereby reserve all rights to dispute the validity, status, or enforceability of any contracts, agreements or leases set forth in Schedule G and to amend or supplement Schedule G as necessary. Additionally, the placing of a contract or lease onto Schedule G shall not be deemed an admission that such contract is an executory contract or unexpired lease, or that it is necessarily a binding, valid, and enforceable contract. Any and all of the Debtors' rights, claims and causes of action with respect to the contracts and agreements listed on Schedule G are hereby reserved and preserved. In addition, the Debtors are continuing their review of all relevant documents and expressly reserve their right to amend all Schedules at a later time as necessary and/or to challenge the classification of any agreement as an executory contract or unexpired lease in any appropriate filing.

The names of employees have been redacted for privacy purposes.

Certain information, such as the contact information of the counterparty, may not be included where such information could not be obtained using the Debtors' reasonable efforts. Listing a contract or agreement on Schedule G does not constitute an admission that such contract or agreement is an executory contract or unexpired lease or that such contract or agreement was in effect on the Petition Date or is valid or enforceable. Expired contracts and leases may have also been inadvertently included. The Debtors hereby reserve all of their rights to dispute the validity, status, or enforceability of any contracts, agreements, or leases set forth in Schedule G and to amend or supplement such Schedule as necessary.

Certain of the leases and contracts listed on Schedule G may contain renewal options, guarantees of payment, indemnifications, options to purchase, rights of first refusal and other miscellaneous rights. Such rights, powers, duties, and obligations are not set forth separately on Schedule G. In addition, the Debtors may have entered into various other types of agreements in the ordinary course of their business, such as supplemental agreements and letter agreements, which documents may not be set forth in Schedule G. The Debtors reserve the right to dispute the effectiveness of any such contract listed on Schedule G or to amend Schedule G at any time to remove any contract.

The Debtors have reserved all rights to dispute or challenge the characterization of any transaction or any document or instrument related to a creditor's claim.

Although the Debtors have made diligent attempts to attribute an executory contract to its rightful Debtor, in certain instances, the Debtors may have inadvertently failed to do so due to the complexity and size of the Debtors' businesses. Accordingly,

the Debtors reserve all of its rights with respect to the named parties of any and all executory contracts, including the right to amend Schedule G.

Omission of a contract or agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. The Debtors' rights under the Bankruptcy Code with respect to any such omitted contract or agreement is not impaired by the omission. Certain Debtors are guarantors and parties to guaranty agreements regarding the Debtors' prepetition credit facility. The guaranty obligations arising under these agreements are reflected on Schedules D and F only.

7. **Specific Statements Disclosures.**

- (a) **Statements, Part 1, Question 1 – Gross Revenue from business.** The Debtors recognize GAAP revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The product is distributed through an exclusive third-party logistics, or 3PL, distribution agent that does not take title to the product. The 3PL distributes Trudhesa to the customers, specialty pharmacies and specialty distributors (collectively referred to as “customers”), who then distribute the product to healthcare providers and patients. Revenue from product sales is recognized when the customer obtains control of the product, which occurs upon transfer of title to the customer. Taxes collected from the customer relating to product sales and remitted to governmental authorities are excluded from revenue.

Revenues from product sales are recorded at the net sales price, or the transaction price, which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, co-pay assistance, chargebacks, rebates, and other allowances that are offered within contracts between us and customers, healthcare providers and other indirect customers relating to the sale of Trudhesa. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect best estimates of the amount of consideration to which the Debtors are entitled based on the terms of the contract.

The components of variable consideration related to product revenue were detailed in the *Debtors' Emergency Motion for Entry of Interim and Final Orders (I) Authorizing the Debtors to Honor and Continue Certain Customer Programs and Customer Obligations in the Ordinary Course of Business, (II) Authorizing*

Banks to Honor and Process Check and Electronic Transfer Requests Related Thereto, and (III) Granting Related Relief [Docket No. 10] and are customary in the pharmaceutical industry.

- (b) **Statements, Part 2, Question 4 – Payments and Transfers to Certain Insiders within 1 year before the filing.** The Debtors reported payments to non-officer insiders within the year prior to the Petition Date. Please see response to Question 30 for officer payments and distributions within the year prior to the Petition Date. The Debtors reserve all rights with respect to the determination or status of a person as an “insider” as defined in section 101(13) of the Bankruptcy Code.
- (c) **Statements, Part 5, Question 10 – Losses from fire, theft, or other casualty.** In normal course, the Debtors’ sales team uses leased vehicles for their travel requirements. On occasion, the vehicles may incur an accident. The Debtors believe they have sufficient insurance to cover any obligation that may arise. Furthermore, the Debtors are not aware of any material disagreements or demands outstanding related to such claims.
- (d) **Statements, Part 6, Question 13 – Transfers not already listed.** A former employee was given an asset that was fully depreciated and deemed to be non-operational for the Debtors. No value was associated with the transfer. The Debtors believe that the asset disposal was worthwhile as to not incur costs to sell and remove the asset from the property.

The Debtors have settled certain claims put forth by former employees. Settlements were covered by insurance. None of these payments were made within the 90 days prior to the Petition Date. None of these payments were made to insiders. The names of employees have been redacted for privacy purposes.

- (e) **Statements, Part 9, Question 16 – Collect and Retain personally identifiable information of customers.** The Debtors do not collect or retain personally identifiable information of their customers or their customers’ patients. Any collection of data containing personally identifiable information is done by third party vendors which remove any personally identifiable information before the data is shared with the Debtors. The Debtors do not receive any personally identifiable information.
- (f) **Statements, Part 9, Question 17– ERISA Plan as an Employee Benefit.** The Debtors sponsor a 401(k) plan for their employees.
- (g) **Statements, Part 10, Question 20 – Off-premises storage.** The Debtors’ sales force uses certain third parties for storage of product samples. In addition, there are four sales team members that have samples at their houses. The Debtors’ track all inventory including these samples to ensure accurate inventory records.
- (h) **Statements, Part 13, Question 25 – Businesses in Which the Debtors Have an Interest.** Impel Pharmaceuticals, Inc. has a 100% interest in Impel NeuroPharma Australia Pty Ltd.

- (i) **Statements, Part 13, Question 26 – Books, records, and financial statements.** The Debtors’ common stock was publicly traded on the Nasdaq stock exchange. As of December 18, 2023, the Debtor’s common stock was suspended from trading. Prior to the suspension of trading on the Nasdaq, the Debtors reported their financial results directly to the U.S. Securities and Exchange Commission for compliance with regulations. Additionally, a copy of financial results have been provided to Oaktree, the senior secured creditor of the Debtors.
- (j) **Statements, Part 13, Question 27 – Inventories – Supervisor and Dates of Last Two Inventories.** The Debtors perform inventory counts of raw materials and finished goods inventories on an annual basis or as needed for operational reasons. The information included in response to Question 27 reflects the last two inventory dates.
- (k) **Statements, Part 13, Question 28 and 29 – Current and Former Officer and Directors.** While the Debtors have made reasonable best efforts to list all applicable officers and directors for each Debtor in response to Statement Questions 28 and 29, some may have been omitted. Disclosures relate specifically to terminated job titles or positions and are not indicative of the individuals’ current employment status with the Debtors.
- (l) **Statements, Part 13, Question 30 – Payments, Distributions, or Withdrawals to Insiders.** Refer to Statement Question 4 for this item.

* * * * *

Debtor Name **Impel Pharmaceuticals Inc.**
United States Bankruptcy Court for the Northern District of Texas
Case number (if known): **23-80016**

☐ Check if this is an amended filing

Official Form 207

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

04/22

The debtor must answer every question. If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and case number (if known).

Part 1: Income

1. Gross Revenue from business

☐ None

Identify the beginning and ending dates of the debtor's fiscal year, which may be a calendar year				Sources of Revenue	Gross Revenue (before deductions and exclusions)	
1.1	From	01/01/23	To	12/19/23	<input checked="" type="checkbox"/> Operating a business <input type="checkbox"/> Other	\$20,080,353.73
1.2	From	01/01/22	To	12/31/22	<input checked="" type="checkbox"/> Operating a business <input type="checkbox"/> Other	\$12,652,179.08
1.3	From	01/01/21	To	12/31/21	<input checked="" type="checkbox"/> Operating a business <input type="checkbox"/> Other	\$668,279.57

2. Non-business revenue

Include revenue regardless of whether that revenue is taxable. Non-business income may include interest, dividends, money collected from lawsuits, and royalties. List each source and the gross revenue for each separately. Do not include revenue listed in line 1.

☐ None

				Description of sources of revenue	Gross Revenue from (before deductions and exclusions)
2.1	From	01/01/23	To	11/30/23	Interest Income \$395,683.65
2.2	From	01/01/22	To	12/31/22	Interest Income \$442,707.09
2.3	From	01/01/21	To	12/31/21	Interest Income \$7,292.73

Part 2: List Certain Transfers Made Before Filing for Bankruptcy

3. Certain payments or transfers to creditors within 90 days before filing this case

List payments of transfers - including expense reimbursements to any creditor, other than regular employee compensation, within 90 days before filing this case unless the aggregate value of all property transferred to that creditor is less than \$7,575. (This amount may be adjusted on 4/01/25 and every 3 years after that with respect to cases filed on or after the date of adjustment.)

☐ None

Creditor's name and address	Dates	Total amount or value	Reasons for payment or transfer <i>Check all that apply</i>
3.1 See attached Exhibit SOFA3		\$18,302,574.95	<input type="checkbox"/> Secured Debt <input type="checkbox"/> Unsecured Loan Payments <input type="checkbox"/> Suppliers or vendors <input type="checkbox"/> Services <input type="checkbox"/> Other

4. Payments or other transfers of property made within 1 year before filing this case that benefited any insider

List payments or transfers, including expense reimbursements, made within 1 year before filing this case on debts owed to an insider or guaranteed or cosigned by an insider unless the aggregate value of all property transferred to or for the benefit of the insider is less than \$7,575. (This amount may be adjusted on 4/01/25 and every 3 years after that with respect to cases filed on or after the date of adjustment.) Do not include any payments listed in line 3. Insiders include officers, directors, and anyone in control of a corporate debtor and their relatives; general partners of a partnership debtor and their relatives; affiliates of the debtor and insiders of such affiliates; and any managing agent of the debtor. 11 U.S.C. § 101(31).

☐ None

Insider's name and address	Dates	Total amount or value	Reasons for payment or transfer
4.1 See attached Exhibit SOFA4		\$510,858.13	

Relationship to debtor

5. Repossessions, foreclosures, and returns

List all property of the debtor that was obtained by a creditor within 1 year before filing this case, including property repossessed by a creditor, sold at a foreclosure sale, transferred by a deed in lieu of foreclosure, or returned to the seller. Do not include property listed in line 6.

☒ None

Creditor's name and address	Description of the property	Date	Value of property
-----------------------------	-----------------------------	------	-------------------

6. Setoffs

List any creditor, including a bank or financial institution, that within 90 days before filing this case set off or otherwise took anything from an account of the debtor without permission or refused to make a payment at the debtor's direction from an account of the debtor because the debtor owed a debt.

☒ None

Creditor's name and address	Description of the action creditor took	Date action was taken	Amount
-----------------------------	---	-----------------------	--------

Part 3: Legal Actions or Assignments

7. Legal actions, administrative proceedings, court actions, executions, attachments, or governmental audits

List the legal actions, proceedings, investigations, arbitrations, mediations, and audits by federal or state agencies in which the debtor was involved in any capacity—within 1 year before filing this case.

☒ None

Case title	Nature of case	Court or agency's name and address	Status of case
------------	----------------	------------------------------------	----------------

8. Assignments and receivership

List any property in the hands of an assignee for the benefit of creditors during the 120 days before filing this case and any property in the hands of a receiver, custodian, or other court-appointed officer within 1 year before filing this case.

☒ None

Custodian's name and address	Description of the property	Value
------------------------------	-----------------------------	-------

Part 4: Certain Gifts and Charitable Contributions

9. List all gifts or charitable contributions the debtor gave to a recipient within 2 years before filing this case unless the aggregate value of gifts to that recipient is less than \$1,000

☒ None

Recipient's name and address	Description of the gifts or contributions	Dates given	Value
------------------------------	---	-------------	-------

Part 5: Certain Losses

10. All losses from fire, theft, or other casualty within 1 year before filing this case.

☐ None

Description of the property lost and how the loss occurred	Amount of payments received for the loss If you have received payments to cover the loss, for example, from insurance, government compensation, or tort liability, list the total received. List unpaid claims on Official Form 106 A/B (Schedule A/B: Assets - Real and Personal Property).	Date of loss	Value of property lost
10.1 See attached Exhibit SOFA10 See Global Notes			

Part 6: Certain Payments of Transfers**11. Payments related to bankruptcy**

List any payments of money or other transfers of property made by the debtor or person acting on behalf of the debtor within 1 year before the filing of this case to another person or entity, including attorneys, that the debtor consulted about debt consolidation or restructuring, seeking bankruptcy relief, or filing a bankruptcy case.

☐ None

Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.1 Teneo Capital LLC		08/09/23 - 12/19/23	\$736,319.17
Email or website address teneofunds.com			
Who made the payment, if not debtor?			
Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.2 Sidley Austin LLP		07/19/23 - 12/19/23	\$1,356,114.13
Email or website address sidley.com			
Who made the payment, if not debtor?			
Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.3 Moelis & Company, LLC		10/20/23 - 12/19/23	\$521,226.87
Email or website address moelis.com			
Who made the payment, if not debtor?			
Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.4 Omni Agent Solutions, Inc.		12/01/23	\$50,000.00
Email or website address omniagentsolutions.com			
Who made the payment, if not debtor?			
Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.5 Fenwick & West		12/19/22 - 12/18/23	\$800,977.63
Email or website address fenwick.com			

Who made the payment, if not debtor?

	Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.6	Sullivan & Cromwell LLP Email or website address sullcrom.com Who made the payment, if not debtor?		12/18/23	\$997,657.18
	Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.7	Paul Weiss Rifkind Wharton & Garrison LLP Email or website address paulweiss.com Who made the payment, if not debtor?		09/05/23 - 12/7/23	\$200,000.00

12. Self-settled trusts of which the debtor is a beneficiary

List any payments or transfers of property made by the debtor or a person acting on behalf of the debtor within 10 years before the filing of this case to a self-settled trust or similar device.
Do not include transfers already listed on this statement.

☒ None

Name of trust or device	Describe any property transferred	Dates transfers were made	Total amount or value
--------------------------------	--	----------------------------------	------------------------------

13. Transfers not already listed on this statement

List any transfers of money or other property - by sale, trade, or any other means - made by the debtor or a person acting on behalf of the debtor within 2 years before the filing of this case to another person, other than property transferred in the ordinary course of business or financial affairs. Include both outright transfers and transfers made as security. Do not include gifts or transfers previously listed on this statement.

☐ None

	Who received transfer? Address.	Description of property transferred or payments received or debts paid in exchange.	Date transfer was made	Total amount or value
13.1	Name and address redacted Relationship to debtor	Settled employee discrimination lawsuits		

Part 7: Previous Locations**14. Previous addresses**

List all previous addresses used by the debtor within 3 years before filing this case and the dates the addresses were used.

☐ Does not apply

	Address	Dates of occupancy
14.1	101 Elliott Ave W Seattle, WA 98119	10/6/21 - 10/31/22

Part 8: Health Care Bankruptcies

15. Health Care bankruptcies

Is the debtor primarily engaged in offering services and facilities for:
- diagnosing or treating injury, deformity, or disease, or
- providing any surgical, psychiatric, drug treatment, or obstetric care?

- ☒ No Go to Part 9.
☐ Yes. Fill in the information below.

Facility name and address

Nature of the business operation, including type of services the debtor provides

If debtor provides meals and housing, number of patients in debtor's care

Location where patient records are maintained

How are records kept?

- ☐ Electronically
☐ Paper

Part 9: Personally Identifiable Information

16. Does the debtor collect and retain personally identifiable information of customers?

- ☒ No
☐ Yes. State the nature of the information collected and retained. _____

Does the debtor have a privacy policy about that information?

- ☐ No
☐ Yes.

17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit?

- ☐ No Go to Part 10.
☒ Yes. Does the debtor serve as plan administrator?

- ☐ No. Go to Part 10.
☒ Yes. Fill in below:

Name of plan

Impel Pharmaceuticals Inc.

Employer identification number of plan

EIN: 26-3058238

Has the plan been terminated?

- ☒ No
☐ Yes

Part 10: Certain Financial Accounts, Safe Deposit Boxes, and Storage Units

18. Closed financial accounts

Within 1 year before filing this case, were any financial accounts or instruments held in the debtor's name, or for the debtor's benefit, closed, sold, moved, or transferred?

Include checking, savings, money market, or other financial accounts; certificates of deposit; and shares in banks, credit unions, brokerage houses, cooperatives, associations, and other financial institutions.

- ☐ None

	Financial institution name and address	Last 4 digits of account number	Type of account	Date account was closed, sold, moved, or transferred	Last balance before closing or transfer
18.1	JP Morgan Chase; 1301 2nd Ave Floor #24; Seattle WA 98101	*7396	<input type="checkbox"/> Checking <input type="checkbox"/> Savings <input checked="" type="checkbox"/> Money Market <input type="checkbox"/> Brokerage <input type="checkbox"/> Other	08/24/23	\$198.58

	Financial institution name and address	Last 4 digits of account number	Type of account	Date account was closed, sold, moved, or transferred	Last balance before closing or transfer
18.2	Silicon Valley Bank; 3003 Tasman Drive; Santa Clara CA 95054	*2337	<input checked="" type="checkbox"/> Checking <input type="checkbox"/> Savings <input type="checkbox"/> Money Market <input type="checkbox"/> Brokerage <input type="checkbox"/> Other	05/30/23	\$0.00

	Financial institution name and address	Last 4 digits of account number	Type of account	Date account was closed, sold, moved, or transferred	Last balance before closing or transfer
18.3	Silicon Valley Bank; 3003 Tasman Drive; Santa Clara CA 95054	*4014	<input checked="" type="checkbox"/> Checking <input type="checkbox"/> Savings <input type="checkbox"/> Money Market <input type="checkbox"/> Brokerage <input type="checkbox"/> Other	05/30/23	\$0.00

	Financial institution name and address	Last 4 digits of account number	Type of account	Date account was closed, sold, moved, or transferred	Last balance before closing or transfer
18.4	Silicon Valley Bank; 3003 Tasman Drive; Santa Clara CA 95054	*5935	<input type="checkbox"/> Checking <input type="checkbox"/> Savings <input checked="" type="checkbox"/> Money Market <input checked="" type="checkbox"/> Brokerage <input type="checkbox"/> Other	04/03/23	\$0.00

19. Safe deposit boxes

List any safe deposit box or other depository for securities, cash, or other valuables the debtor now has or did have within 1 year before filing this case.

☒ None

Depository institution name and address	Names of anyone with access to it. Address	Description of contents	Does debtor still have it?
			<input type="checkbox"/> No <input type="checkbox"/> Yes

20. Off-premises storage

List any property kept in storage units or warehouses within 1 year before filing this case. Do not include facilities that are in a part of a building in which the debtor does business.

☐ None

Facility name and address	Names of anyone with access to it. Address	Description of contents	Does debtor still have it?
20.1 See attached Exhibit SOFA20			<input type="checkbox"/> No <input type="checkbox"/> Yes

Part 11: Property the Debtor Holds or Controls That the Debtor Does Not Own

21. Property held for another

List any property that the debtor holds or controls that another entity owns. Include any property borrowed from, being stored for, or held in trust. Do not list leased or rented property.

☒ None

Owner's name and address	Location of the property	Description of the property	Value
--------------------------	--------------------------	-----------------------------	-------

Part 12: Details About Environmental Information

For the purpose of Part 12, the following definitions apply:

- Environmental law means any statute or governmental regulation that concerns pollution, contamination, or hazardous material, regardless of the medium affected (air, land, water, or any other medium)
- Site means any location, facility, or property, including disposal sites, that the debtor now owns, operates, or utilizes or that the debtor formerly owned, operated, or utilized.
- Hazardous material means anything that an environmental law defines as hazardous or toxic, or describes as a pollutant, contaminant, or a similarly harmful substance.

22. Has the debtor been a party in any judicial or administrative proceeding under any environmental law? Include settlements and orders.

- ☒ No
☐ Yes. Provide details below.

Case title	Court or agency name and address	Nature of the case	Status of case
Case number			<input type="checkbox"/> Pending <input type="checkbox"/> On appeal <input type="checkbox"/> Concluded

23. Has any governmental unit otherwise notified the debtor that the debtor may be liable or potentially liable under or in violation of an environmental law?

- ☒ No
☐ Yes. Provide details below.

Site name and address	Governmental unit name and address	Environmental law, if known	Date of notice
-----------------------	------------------------------------	-----------------------------	----------------

24. Has the debtor notified any governmental unit of any release of hazardous material?

- ☒ No
☐ Yes. Provide details below.

Site name and address	Governmental unit name and address	Environmental law, if known	Date of notice
-----------------------	------------------------------------	-----------------------------	----------------

Part 13: Details About the Debtor's Business or Connections to Any Business

25. Other businesses in which the debtor has or has had an interest

List any business for which the debtor was an owner, partner, member, or otherwise a person in control within 6 years before filing this case. Include this information even if already listed in the Schedules.

☐ None

Business name and address	Describe the nature of the business	Employer identification number. Dates business existed
25.1 Impel NeuroPharma Australia Pty Ltd.	Initially established to conduct clinical trials. For last several years has had no activity, and only minimal holdings of cash.	ABN: 31 611 195 567 08/03/16 - Present

26. Books, records, and financial statements

26a. List all accountants and bookkeepers who maintained the debtor's books and records within 2 years before filing this case.

☐ None

Name and address	Dates of service
26a.1 John Leaman 201 Elliott Ave W Ste 260 Seattle, WA 98119	06/24/19 - 03/10/23
26a.2 Rajiv Amin	07/31/21 - 09/08/23

201 Elliott Ave W
Ste 260
Seattle, WA 98119

26a.3 Michael Kalb
201 Elliott Ave W
Ste 260
Seattle, WA 98119
05/10/23 - 12/31/23

26b. List all firms or individuals who have audited, compiled, or reviewed debtor's books of account and records or prepared a financial statement within 2 years before filing this case.

☐ None

	Name and address	Dates of service
26b.1	Ernst & Young LLP 920 Fifth Ave Seattle, WA 98104	2017 - 2023

26c. List all firms or individuals who were in possession of the debtor's books of account and records when this case is filed.

☒ None

	Name and address	If any books of account and records are unavailable, explain why
--	-------------------------	---

26d. List all financial institutions, creditors, and other parties, including mercantile and trade agencies, to whom the debtor issued a financial statement within 2 years before filing this case.

☐ None

	Name and address
26d.1	U.S. Securities and Exchange Commission
26d.2	Oaktree
26d.3	NASDAQ
26d.4	This is a public company where financial statement access is not limited. See Gobal Notes

27. Inventories

Have any inventories of the debtor's property been taken within 2 years before filing this case?

- ☐ No
☒ Yes. Give the details about the two most recent inventories

	Name of the person who supervised the taking of the inventory	Date of inventory	The dollar amount and basis (cost, market, or other basis) of each inventory
27.1	Freudenberg Medical 5050 Rivergrade Rd Baldwin Park, CA 91706	12/22/22	\$1,962,611.00 Standard Cost
	Name and address of the person who has possession of inventory records Scott Youmans		

	Name of the person who supervised the taking of the inventory	Date of inventory	The dollar amount and basis (cost, market, or other basis) of each inventory
27.2	PCI Pharma Services, Inc. 4545 Assembly Dr Rockford, IL 61109	12/16/22	\$4,615,377.54 Standard Cost
	Name and address of the person who has possession of inventory records Scott Youmans		

	Name of the person who supervised the taking of the inventory	Date of inventory	The dollar amount and basis (cost, market, or other basis) of each inventory
27.3	15 Ingram Blvd, St 100 La Vergne, TN 37086	12/21/22	\$1,783,422.24 Standard Cost
	Name and address of the person who has possession of inventory records Scott Youmans		

28. List the debtor's officers, directors, managing members, general partners, members in control, controlling shareholders, or other people in control of the debtor at the time of the filing of this case.

	Name	Address	Position and nature of any interest	% of interest, if any
28.1	Paolillo, Leonard	201 Elliott Ave W Ste 260 Seattle, WA 98119	CCO, Interim CEO	
28.2	Kalb, Michael	201 Elliott Ave W Ste 260 Seattle, WA 98119	CFO	
28.3	Hoekman, John	201 Elliott Ave W Ste 260 Seattle, WA 98119	CTO, CDO	
28.4	Cline, Darren	201 Elliott Ave W Ste 260 Seattle, WA 98119	Director	
28.5	Wilfong, Diane	201 Elliott Ave W Ste 260 Seattle, WA 98119	Director	
28.6	Nelson, Timothy	201 Elliott Ave W Ste 260 Seattle, WA 98119	Director	
28.7	Allison, David	201 Elliott Ave W Ste 260 Seattle, WA 98119	Director	
28.8	KKR	201 Elliott Ave W Ste 260 Seattle, WA 98119	Shareholder	Over 10%
28.9	Brandon Smith	201 Elliott Ave W Ste 260 Seattle, WA 98119	CRO	

29. Within 1 year before the filing of this case, did the debtor have officers, directors, managing members, general partners, members in control of the debtor, or shareholders in control of the debtor who no longer hold these positions?

- ☐ No
☒ Yes. Identify below.

	Name	Address	Position and nature of any interest	Period during which position or interest was held
29.1	Adams, Adrian	201 Elliott Ave W Ste 260 Seattle, WA 98119	Chairman & CEO	05/04/20 - 11/04/23
29.2	Leaman, John	201 Elliott Ave W Ste 260 Seattle, WA 98119	CFO	06/24/19 - 03/10/23
29.3	Shrewsbury, Stephen	201 Elliott Ave W Ste 260 Seattle, WA 98119	CMO	02/14/17 - 03/31/23
29.4	Parker, Stewart	201 Elliott Ave W Ste 260 Seattle, WA 98119	Director	Departure 04/10/23
29.5	Shah, Mahendra	201 Elliott Ave W Ste 260 Seattle, WA 98119	Director	Departure 09/06/23

30. Payments, distributions, or withdrawals credited or given to insiders

Within 1 year before filing this case, did the debtor provide an insider with value in any form, including salary, other compensation, draws, bonuses, loans, credits on loans, stock redemptions, and options exercised?

- ☐ No
☒ Yes. Identify below.

	Name and address of recipient	Amount of money or description and value of property	Dates	Reason for providing this value
30.1	See attached Exhibit SOFA30 Relationship to debtor	\$3,780,746.45		

31. Within 6 years before filing this case, has the debtor been a member of any consolidated group for tax purposes?

- ☐ No
☒ Yes. Identify below.

	Name of the parent corporation	Employer identification number of the parent corporation
31.1	Impel Pharmaceuticals, Inc.	26-3058238

32. Within 6 years before filing this case, has the debtor as an employer been responsible for contributing to a pension fund?

- ☒ No
☐ Yes. Identify below.

	Name of the pension fund	Employer identification number of the pension fund

In re Impel Pharmaceuticals Inc.


Part 14: Signature and Declaration

WARNING Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

I have examined the information in this *Statement of Financial Affairs* and any attachments and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on. 1/18/2024
MM / DD / YYYY


Signature of individual signing on behalf of the debtor

Printed name Brandon D. Smith

Position or relationship to the debtor Chief Restructuring Officer

Are additional pages to *Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy* (Official Form 207) attached?

☐ No

☒ Yes

STATEMENT OF FINANCIAL AFFAIRS

**EXHIBIT
PART 2, QUESTION 3**

**CERTAIN PAYMENTS OR TRANSFERS TO CREDITORS
WITHIN 90 DAYS BEFORE FILING THIS CASE**

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
ADP	9/29/2023	\$ 2,692.34	Suppliers or vendors
ADP	9/29/2023	\$ 754.19	Suppliers or vendors
ADP	10/10/2023	\$ 4,494.00	Suppliers or vendors
ADP	10/15/2023	\$ 68,085.56	Other (401k contributions)
ADP	10/27/2023	\$ 2,686.29	Suppliers or vendors
ADP	10/30/2023	\$ 727.66	Suppliers or vendors
ADP	11/10/2023	\$ 4,146.30	Suppliers or vendors
ADP	11/15/2023	\$ 58,092.14	Other (401k contributions)
ADP	11/24/2023	\$ 600.87	Suppliers or vendors
ADP	11/28/2023	\$ 2,119.60	Other (401k contributions)
ADP	12/1/2023	\$ 2,851.51	Suppliers or vendors
ADP	12/11/2023	\$ 3,753.75	Suppliers or vendors
ADP	12/14/2023	\$ 180,000.00	Other (Wages)
ADP	12/15/2023	\$ 25,599.43	Other (401k contributions)
ADP	12/15/2023	\$ 23,991.15	Other (401k contributions)
ADP	12/15/2023	\$ 17,594.57	Other (401k contributions)
ADP Total		\$ 398,189.36	
Aetna	10/3/2023	\$ 125,658.13	Suppliers or vendors
Aetna	11/2/2023	\$ 120,014.41	Suppliers or vendors
Aetna	11/30/2023	\$ 101,577.23	Suppliers or vendors
Aetna Total		\$ 347,249.77	
Amex	9/22/2023	\$ 93,135.76	Suppliers or vendors
AMEX	9/28/2023	\$ 29,260.67	Suppliers or vendors
AMEX	9/28/2023	\$ 22,189.28	Suppliers or vendors
AMEX	9/28/2023	\$ 18,911.33	Suppliers or vendors
AMEX	9/28/2023	\$ 17,910.86	Suppliers or vendors
AMEX	9/28/2023	\$ 17,111.77	Suppliers or vendors
AMEX	9/28/2023	\$ 15,999.83	Suppliers or vendors
AMEX	9/28/2023	\$ 8,172.39	Suppliers or vendors
AMEX	9/28/2023	\$ 5,004.51	Suppliers or vendors
AMEX	10/26/2023	\$ 64,212.55	Suppliers or vendors
AMEX	10/26/2023	\$ 59,587.77	Suppliers or vendors
AMEX	10/26/2023	\$ 6,891.73	Suppliers or vendors
AMEX	10/26/2023	\$ 4,095.75	Suppliers or vendors
AMEX	11/9/2023	\$ 72,604.08	Suppliers or vendors
AMEX	11/9/2023	\$ 72,338.16	Suppliers or vendors
AMEX	11/9/2023	\$ 1,250.34	Suppliers or vendors
AMEX	11/30/2023	\$ 20,301.12	Suppliers or vendors
AMEX	12/6/2023	\$ 26,145.32	Suppliers or vendors
AMEX	12/6/2023	\$ 848.60	Suppliers or vendors
AMEX	12/15/2023	\$ 45,595.21	Suppliers or vendors
AMEX	12/15/2023	\$ 27,922.60	Suppliers or vendors
Amex Total		\$ 629,489.63	
Ascent Health Services LLC	9/28/2023	\$ 240,663.61	Suppliers or vendors
Ascent Health Services LLC	10/31/2023	\$ 286,863.67	Suppliers or vendors
Ascent Health Services LLC	11/30/2023	\$ 300,223.37	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Ascent Health Services LLC	12/18/2023	\$ 199,597.44	Suppliers or vendors
Ascent Health Services LLC	12/18/2023	\$ 199,497.44	Suppliers or vendors
Ascent Health Services LLC	12/18/2023	\$ (199,497.44)	Suppliers or vendors
Ascent Health Services LLC Total		\$ 1,027,348.09	
ASPN Pharmacies, LLC	10/4/2023	\$ 56,800.10	Suppliers or vendors
ASPN Pharmacies, LLC	10/11/2023	\$ 158,204.97	Suppliers or vendors
ASPN Pharmacies, LLC	10/25/2023	\$ 171,384.79	Suppliers or vendors
ASPN Pharmacies, LLC	11/8/2023	\$ 291,257.43	Suppliers or vendors
ASPN Pharmacies, LLC	11/8/2023	\$ 65,861.50	Suppliers or vendors
ASPN Pharmacies, LLC	11/21/2023	\$ 146,989.41	Suppliers or vendors
ASPN Pharmacies, LLC	11/21/2023	\$ 65,642.90	Suppliers or vendors
ASPN Pharmacies, LLC	12/18/2023	\$ 148,655.15	Suppliers or vendors
ASPN Pharmacies, LLC	12/19/2023	\$ 60,393.50	Suppliers or vendors
ASPN Pharmacies, LLC Total		\$ 1,165,189.75	
Aviva Kamm Law PLLC	10/11/2023	\$ 6,660.00	Suppliers or vendors
Aviva Kamm Law PLLC	11/15/2023	\$ 2,820.00	Suppliers or vendors
Aviva Kamm Law PLLC	12/4/2023	\$ 120.00	Suppliers or vendors
Aviva Kamm Law PLLC Total		\$ 9,600.00	
Axtria, Inc.	10/4/2023	\$ 23,000.00	Suppliers or vendors
Axtria, Inc.	10/4/2023	\$ 20,625.00	Suppliers or vendors
Axtria, Inc.	10/4/2023	\$ 15,250.00	Suppliers or vendors
Axtria, Inc.	10/4/2023	\$ 15,250.00	Suppliers or vendors
Axtria, Inc.	10/4/2023	\$ 12,500.00	Suppliers or vendors
Axtria, Inc.	10/4/2023	\$ 12,000.00	Suppliers or vendors
Axtria, Inc. Total		\$ 98,625.00	
Baker Tilly US, LLP	10/4/2023	\$ 191.98	Suppliers or vendors
Baker Tilly US, LLP	10/11/2023	\$ 1,772.63	Suppliers or vendors
Baker Tilly US, LLP	11/15/2023	\$ 30,888.88	Suppliers or vendors
Baker Tilly US, LLP	11/15/2023	\$ 1,772.63	Suppliers or vendors
Baker Tilly US, LLP	11/30/2023	\$ 10,423.60	Suppliers or vendors
Baker Tilly US, LLP	11/30/2023	\$ 9,079.45	Suppliers or vendors
Baker Tilly US, LLP	11/30/2023	\$ 6,213.24	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 21,468.48	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 7,701.00	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 6,213.24	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 5,358.50	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 1,772.63	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 1,772.63	Suppliers or vendors
Baker Tilly US, LLP	12/14/2023	\$ 1,554.27	Suppliers or vendors
Baker Tilly US, LLP Total		\$ 106,183.16	
BioMed Realty	10/4/2023	\$ 87,672.46	Other (rent)
BioMed Realty	10/4/2023	\$ 255.00	Other (rent)
BioMed Realty	11/8/2023	\$ 86,572.46	Other (rent)
BioMed Realty	11/8/2023	\$ 255.00	Other (rent)
BioMed Realty	12/11/2023	\$ 87,122.46	Other (rent)
BioMed Realty	12/11/2023	\$ 255.00	Other (rent)

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
BioMed Realty Total		\$ 262,132.38	
Bridge Commercial Real Estate	10/3/2023	\$ 50,000.00	Other (construction)
Bridge Commercial Real Estate	10/4/2023	\$ 19,106.88	Other (rent)
Bridge Commercial Real Estate	10/17/2023	\$ 95,824.24	Other (construction)
Bridge Commercial Real Estate	10/18/2023	\$ 0.60	Other (construction)
Bridge Commercial Real Estate	12/14/2023	\$ 19,106.88	Other (rent)
Bridge Commercial Real Estate Total		\$ 184,038.60	
C.H. Robinson Worldwide	10/4/2023	\$ 977.66	Suppliers or vendors
C.H. Robinson Worldwide	10/4/2023	\$ 805.71	Suppliers or vendors
C.H. Robinson Worldwide	10/4/2023	\$ 400.00	Suppliers or vendors
C.H. Robinson Worldwide	10/4/2023	\$ 400.00	Suppliers or vendors
C.H. Robinson Worldwide	10/4/2023	\$ 400.00	Suppliers or vendors
C.H. Robinson Worldwide	10/4/2023	\$ 400.00	Suppliers or vendors
C.H. Robinson Worldwide	10/4/2023	\$ 400.00	Suppliers or vendors
C.H. Robinson Worldwide	11/8/2023	\$ 18,041.95	Suppliers or vendors
C.H. Robinson Worldwide	12/4/2023	\$ 2,119.54	Suppliers or vendors
C.H. Robinson Worldwide	12/14/2023	\$ 1,875.09	Suppliers or vendors
C.H. Robinson Worldwide	12/14/2023	\$ 1,875.09	Suppliers or vendors
C.H. Robinson Worldwide	12/14/2023	\$ 500.00	Suppliers or vendors
C.H. Robinson Worldwide Total		\$ 28,195.04	
Cardinal Health	10/4/2023	\$ 33,251.59	Suppliers or vendors
Cardinal Health	10/11/2023	\$ 26,840.40	Suppliers or vendors
Cardinal Health	11/8/2023	\$ 41,349.54	Suppliers or vendors
Cardinal Health	11/15/2023	\$ 23,720.62	Suppliers or vendors
Cardinal Health	12/14/2023	\$ 30,306.72	Suppliers or vendors
Cardinal Health Total		\$ 155,468.87	
Caremark LLC	10/10/2023	\$ 4,235.85	Other (rebates)
Caremark LLC	10/10/2023	\$ 1,311.98	Other (rebates)
Caremark LLC	11/8/2023	\$ 3,448.65	Other (rebates)
Caremark LLC	11/8/2023	\$ 1,967.97	Other (rebates)
Caremark LLC	12/4/2023	\$ 4,685.71	Other (rebates)
Caremark LLC	12/4/2023	\$ 1,311.98	Other (rebates)
Caremark LLC	12/18/2023	\$ 5,660.31	Other (rebates)
Caremark LLC Total		\$ 22,622.45	
Carepoint Healthcare	9/28/2023	\$ 140,365.92	Suppliers or vendors
Carepoint Healthcare	10/11/2023	\$ 118,202.88	Suppliers or vendors
Carepoint Healthcare	10/11/2023	\$ 25,040.40	Suppliers or vendors
Carepoint Healthcare	10/25/2023	\$ 113,585.58	Suppliers or vendors
Carepoint Healthcare	11/8/2023	\$ 107,121.36	Suppliers or vendors
Carepoint Healthcare	11/8/2023	\$ 26,135.39	Suppliers or vendors
Carepoint Healthcare	11/21/2023	\$ 137,595.54	Suppliers or vendors
Carepoint Healthcare	12/4/2023	\$ 127,437.48	Suppliers or vendors
Carepoint Healthcare	12/4/2023	\$ 23,390.32	Suppliers or vendors
Carepoint Healthcare	12/18/2023	\$ 127,437.48	Suppliers or vendors
Carepoint Healthcare	12/18/2023	\$ 127,437.48	Suppliers or vendors
Carepoint Healthcare	12/18/2023	\$ 111,738.66	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Carepoint Healthcare	12/18/2023	\$ (111,738.66)	Suppliers or vendors
Carepoint Healthcare	12/18/2023	\$ (127,437.48)	Suppliers or vendors
Carepoint Healthcare Total		\$ 946,312.35	
CCG Corporate Mailings, Inc.	10/4/2023	\$ 27,298.53	Suppliers or vendors
CCG Corporate Mailings, Inc.	10/4/2023	\$ 26,224.96	Suppliers or vendors
CCG Corporate Mailings, Inc.	10/4/2023	\$ 11,139.00	Suppliers or vendors
CCG Corporate Mailings, Inc.	10/4/2023	\$ 7,297.42	Suppliers or vendors
CCG Corporate Mailings, Inc.	10/4/2023	\$ 2,180.09	Suppliers or vendors
CCG Corporate Mailings, Inc.	10/4/2023	\$ 1,328.55	Suppliers or vendors
CCG Corporate Mailings, Inc.	11/8/2023	\$ 16,272.04	Suppliers or vendors
CCG Corporate Mailings, Inc.	11/8/2023	\$ 11,263.01	Suppliers or vendors
CCG Corporate Mailings, Inc.	11/8/2023	\$ 9,027.49	Suppliers or vendors
CCG Corporate Mailings, Inc.	11/8/2023	\$ 1,264.37	Suppliers or vendors
CCG Corporate Mailings, Inc.	12/14/2023	\$ 5,284.20	Suppliers or vendors
CCG Corporate Mailings, Inc.	12/14/2023	\$ 1,264.37	Suppliers or vendors
CCG Corporate Mailings, Inc. Total		\$ 119,844.03	
CDW	11/8/2023	\$ 319.17	Suppliers or vendors
CDW	11/8/2023	\$ 82.69	Suppliers or vendors
CDW	11/8/2023	\$ 52.29	Suppliers or vendors
CDW	12/4/2023	\$ 8,358.42	Suppliers or vendors
CDW Total		\$ 8,812.57	
Clark Nuber	12/1/2023	\$ 15,000.00	Suppliers or vendors
Clark Nuber	12/18/2023	\$ 6,500.00	Suppliers or vendors
Clark Nuber Total		\$ 21,500.00	
Cline, Darren	12/14/2023	\$ 12,500.00	Other (Board Fees)
Cline, Darren Total		\$ 12,500.00	
Clinigen CSM, Inc	10/4/2023	\$ 3,273.39	Suppliers or vendors
Clinigen CSM, Inc	10/4/2023	\$ 2,368.28	Suppliers or vendors
Clinigen CSM, Inc	10/4/2023	\$ 633.98	Suppliers or vendors
Clinigen CSM, Inc	11/8/2023	\$ 3,273.39	Suppliers or vendors
Clinigen CSM, Inc	11/8/2023	\$ 2,563.24	Suppliers or vendors
Clinigen CSM, Inc	11/8/2023	\$ 633.98	Suppliers or vendors
Clinigen CSM, Inc Total		\$ 12,746.26	
CMTJ & Associates (McGoldrick, Claudia)	10/4/2023	\$ 6,000.00	Suppliers or vendors
CMTJ & Associates (McGoldrick, Claudia)	10/4/2023	\$ 6,000.00	Suppliers or vendors
CMTJ & Associates (McGoldrick, Claudia)	11/8/2023	\$ 6,000.00	Suppliers or vendors
CMTJ & Associates (McGoldrick, Claudia)	12/14/2023	\$ 6,000.00	Suppliers or vendors
CMTJ & Associates (McGoldrick, Claudia) Total		\$ 24,000.00	
Concur	10/4/2023	\$ 6,414.16	Suppliers or vendors
Concur	11/8/2023	\$ 6,414.16	Suppliers or vendors
Concur	12/4/2023	\$ 6,414.16	Suppliers or vendors
Concur	12/14/2023	\$ 6,414.16	Suppliers or vendors
Concur Total		\$ 25,656.64	
Connor Group	11/15/2023	\$ 10,361.75	Suppliers or vendors
Connor Group	11/30/2023	\$ 30,877.00	Suppliers or vendors
Connor Group Total		\$ 41,238.75	

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Crisp Thinking LTD	10/4/2023	\$ 5,000.00	Suppliers or vendors
Crisp Thinking LTD	11/8/2023	\$ 5,000.00	Suppliers or vendors
Crisp Thinking LTD	12/1/2023	\$ 5,000.00	Suppliers or vendors
Crisp Thinking LTD	12/14/2023	\$ 3,870.97	Suppliers or vendors
Crisp Thinking LTD Total		\$ 18,870.97	
Cubework	11/2/2023	\$ 5,732.30	Suppliers or vendors
Cubework	11/2/2023	\$ 286.62	Suppliers or vendors
Cubework	11/2/2023	\$ 0.20	Suppliers or vendors
Cubework	11/9/2023	\$ 5,159.07	Suppliers or vendors
Cubework	12/4/2023	\$ 5,732.30	Suppliers or vendors
Cubework	12/4/2023	\$ 573.23	Suppliers or vendors
Cubework	12/4/2023	\$ 286.41	Suppliers or vendors
Cubework Total		\$ 17,770.13	
D2 Branding LLC	10/13/2023	\$ 14,043.28	Suppliers or vendors
D2 Branding LLC	10/13/2023	\$ 1,687.50	Suppliers or vendors
D2 Branding LLC Total		\$ 15,730.78	
David Allison	12/14/2023	\$ 20,625.00	Other (Board Fees)
David Allison Total		\$ 20,625.00	
Deerfield Agency, LLC	10/4/2023	\$ 19,000.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 8,786.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 7,811.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 6,594.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 5,500.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 4,500.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 2,500.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 2,500.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 837.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 500.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 500.00	Suppliers or vendors
Deerfield Agency, LLC	10/4/2023	\$ 409.00	Suppliers or vendors
Deerfield Agency, LLC	11/30/2023	\$ 5,000.00	Suppliers or vendors
Deerfield Agency, LLC Total		\$ 64,437.00	
Delaware Secretary of State	9/25/2023	\$ 40,600.00	Other (Taxes)
Delaware Secretary of State	12/14/2023	\$ 40,000.00	Other (Taxes)
Delaware Secretary of State	12/14/2023	\$ 600.00	Other (Taxes)
Delaware Secretary of State Total		\$ 81,200.00	
Delta Dental	10/4/2023	\$ 10,461.30	Suppliers or vendors
Delta Dental	11/2/2023	\$ 10,304.20	Suppliers or vendors
Delta Dental	11/2/2023	\$ 346.10	Suppliers or vendors
Delta Dental	12/1/2023	\$ 8,609.10	Suppliers or vendors
Delta Dental Total		\$ 29,720.70	
Dividend Group LLC	11/21/2023	\$ 4,000.00	Suppliers or vendors
Dividend Group LLC	12/18/2023	\$ 4,000.00	Suppliers or vendors
Dividend Group LLC Total		\$ 8,000.00	
Elixir Health Public Relations	10/11/2023	\$ 19,101.25	Suppliers or vendors
Elixir Health Public Relations	12/14/2023	\$ 2,180.00	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Elixir Health Public Relations Total		\$ 21,281.25	
Emerald Search Partners	10/4/2023	\$ 1,902.94	Suppliers or vendors
Emerald Search Partners	10/4/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	10/4/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	10/11/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	10/18/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	10/25/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	11/8/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	11/8/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	11/8/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	11/21/2023	\$ 1,463.80	Suppliers or vendors
Emerald Search Partners	11/30/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners	12/4/2023	\$ 1,097.85	Suppliers or vendors
Emerald Search Partners	12/14/2023	\$ 1,829.75	Suppliers or vendors
Emerald Search Partners Total		\$ 22,762.09	
Emkay, Inc.	9/29/2023	\$ 98,834.95	Suppliers or vendors
Emkay, Inc.	10/13/2023	\$ 55,190.43	Suppliers or vendors
Emkay, Inc.	10/27/2023	\$ 19,916.53	Suppliers or vendors
Emkay, Inc.	11/1/2023	\$ 78,420.61	Suppliers or vendors
Emkay, Inc.	11/3/2023	\$ 5,884.09	Suppliers or vendors
Emkay, Inc.	11/10/2023	\$ 61,580.34	Suppliers or vendors
Emkay, Inc.	11/10/2023	\$ 7,138.08	Suppliers or vendors
Emkay, Inc.	11/17/2023	\$ 3,708.41	Suppliers or vendors
Emkay, Inc.	11/24/2023	\$ 3,778.62	Suppliers or vendors
Emkay, Inc.	12/1/2023	\$ 29,050.62	Suppliers or vendors
Emkay, Inc.	12/1/2023	\$ 4,693.48	Suppliers or vendors
Emkay, Inc.	12/8/2023	\$ 2,947.44	Suppliers or vendors
Emkay, Inc.	12/12/2023	\$ 21,519.13	Suppliers or vendors
Emkay, Inc.	12/15/2023	\$ 5,061.40	Suppliers or vendors
Emkay, Inc.	12/18/2023	\$ 67,300.00	Suppliers or vendors
Emkay, Inc. Total		\$ 465,024.13	
Ernst & Young	9/22/2023	\$ 250,000.00	Suppliers or vendors
Ernst & Young	11/6/2023	\$ 40,000.00	Suppliers or vendors
Ernst & Young	12/14/2023	\$ 8,755.00	Suppliers or vendors
Ernst & Young Total		\$ 298,755.00	
Express Scripts Inc	9/28/2023	\$ 1,020.98	Other (rebates)
Express Scripts Inc	10/31/2023	\$ 2,382.29	Other (rebates)
Express Scripts Inc	10/31/2023	\$ 1,592.70	Other (rebates)
Express Scripts Inc	11/30/2023	\$ 12,326.76	Other (rebates)
Express Scripts Inc	11/30/2023	\$ 2,769.47	Other (rebates)
Express Scripts Inc	12/18/2023	\$ 11,971.71	Other (rebates)
Express Scripts Inc	12/18/2023	\$ 2,034.92	Other (rebates)
Express Scripts Inc Total		\$ 34,098.83	
Fenwick & West	10/4/2023	\$ 150,000.00	Suppliers or vendors
Fenwick & West	10/4/2023	\$ 5,900.00	Suppliers or vendors
Fenwick & West	10/11/2023	\$ 150,000.00	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Fenwick & West	10/11/2023	\$ 5,900.00	Suppliers or vendors
Fenwick & West	11/8/2023	\$ 150,000.00	Suppliers or vendors
Fenwick & West	11/8/2023	\$ 5,900.00	Suppliers or vendors
Fenwick & West	11/8/2023	\$ 5,900.00	Suppliers or vendors
Fenwick & West	11/21/2023	\$ 150,000.00	Suppliers or vendors
Fenwick & West	11/21/2023	\$ 5,506.67	Suppliers or vendors
Fenwick & West	12/18/2023	\$ 150,000.00	Suppliers or vendors
Fenwick & West Total		\$ 779,106.67	
Food and Drug Administration	10/4/2023	\$ 416,734.00	Other (Regulatory Fee)
Food and Drug Administration Total		\$ 416,734.00	
Freudenberg Medical	9/28/2023	\$ 86,072.20	Suppliers or vendors
Freudenberg Medical	9/28/2023	\$ 2,887.95	Suppliers or vendors
Freudenberg Medical Total		\$ 88,960.15	
Good Apple	10/4/2023	\$ 131,602.47	Suppliers or vendors
Good Apple	10/11/2023	\$ 200,000.00	Suppliers or vendors
Good Apple Total		\$ 331,602.47	
	9/22/2023	\$ 1,457.40	Other (EE reimbursement)
	10/18/2023	\$ 2,722.11	Other (EE reimbursement)
	11/15/2023	\$ 864.26	Other (EE reimbursement)
	12/14/2023	\$ 1,843.91	Other (EE reimbursement)
	12/15/2023	\$ 1,937.74	Other (EE reimbursement)
Total		\$ 8,825.42	
Imprint Science	10/4/2023	\$ 12,420.00	Suppliers or vendors
Imprint Science	10/4/2023	\$ 6,838.16	Suppliers or vendors
Imprint Science	10/4/2023	\$ 2,880.00	Suppliers or vendors
Imprint Science	10/4/2023	\$ 2,455.00	Suppliers or vendors
Imprint Science Total		\$ 24,593.16	
Integrichain	9/26/2023	\$ 100,000.00	Other (rebates)
Integrichain	9/28/2023	\$ 52,020.80	Suppliers or vendors
Integrichain	10/4/2023	\$ 16,800.00	Suppliers or vendors
Integrichain	10/4/2023	\$ 15,750.00	Suppliers or vendors
Integrichain	10/4/2023	\$ 250.00	Suppliers or vendors
Integrichain	10/11/2023	\$ 28,425.00	Suppliers or vendors
Integrichain	12/1/2023	\$ 35,642.68	Suppliers or vendors
Integrichain	12/4/2023	\$ 25,000.00	Suppliers or vendors
Integrichain	12/14/2023	\$ 50,000.00	Suppliers or vendors
Integrichain	12/14/2023	\$ 31,525.00	Suppliers or vendors
Integrichain	12/14/2023	\$ 27,011.25	Suppliers or vendors
Integrichain	12/14/2023	\$ 17,640.00	Suppliers or vendors
Integrichain	12/14/2023	\$ 16,537.50	Suppliers or vendors
Integrichain	12/14/2023	\$ 7,717.50	Suppliers or vendors
Integrichain	12/14/2023	\$ 250.00	Suppliers or vendors
Integrichain	12/18/2023	\$ 130,000.00	Suppliers or vendors
Integrichain Total		\$ 554,569.73	
IPFS	12/18/2023	\$ 39,675.99	Suppliers or vendors
IPFS Total		\$ 39,675.99	

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Jennason LLC	10/4/2023	\$ 6,470.00	Suppliers or vendors
Jennason LLC	10/4/2023	\$ 4,875.00	Suppliers or vendors
Jennason LLC	10/4/2023	\$ 3,325.00	Suppliers or vendors
Jennason LLC	11/15/2023	\$ 8,955.00	Suppliers or vendors
Jennason LLC	12/4/2023	\$ 7,225.00	Suppliers or vendors
Jennason LLC Total		\$ 30,850.00	
Juice Pharma Worldwide	10/4/2023	\$ 50,181.03	Suppliers or vendors
Juice Pharma Worldwide Total		\$ 50,181.03	
KKR Iris Investors, LLC (Ali Satvat)	12/14/2023	\$ 13,750.00	Other (Board Fees)
KKR Iris Investors, LLC (Ali Satvat) Total		\$ 13,750.00	
Life Storage/Warehouse Anywhere	10/4/2023	\$ 9,720.91	Suppliers or vendors
Life Storage/Warehouse Anywhere	10/11/2023	\$ 8,496.85	Suppliers or vendors
Life Storage/Warehouse Anywhere	10/11/2023	\$ 1,000.00	Suppliers or vendors
Life Storage/Warehouse Anywhere	11/8/2023	\$ 8,075.12	Suppliers or vendors
Life Storage/Warehouse Anywhere	11/30/2023	\$ 8,167.78	Suppliers or vendors
Life Storage/Warehouse Anywhere	12/14/2023	\$ 6,970.85	Suppliers or vendors
Life Storage/Warehouse Anywhere Total		\$ 42,431.51	
MAHEC	12/1/2023	\$ 15,000.00	Suppliers or vendors
MAHEC Total		\$ 15,000.00	
Med Communications, Inc.	10/4/2023	\$ 28,942.00	Suppliers or vendors
Med Communications, Inc.	10/4/2023	\$ 800.00	Suppliers or vendors
Med Communications, Inc.	10/11/2023	\$ 15,400.00	Suppliers or vendors
Med Communications, Inc.	11/8/2023	\$ 25,350.00	Suppliers or vendors
Med Communications, Inc.	11/8/2023	\$ 800.00	Suppliers or vendors
Med Communications, Inc.	11/8/2023	\$ 800.00	Suppliers or vendors
Med Communications, Inc.	11/15/2023	\$ 29,450.00	Suppliers or vendors
Med Communications, Inc.	11/15/2023	\$ 15,605.00	Suppliers or vendors
Med Communications, Inc.	12/14/2023	\$ 13,195.00	Suppliers or vendors
Med Communications, Inc.	12/14/2023	\$ 12,015.00	Suppliers or vendors
Med Communications, Inc. Total		\$ 142,357.00	
MiPharm (EUR)	9/28/2023	\$ 110,429.83	Suppliers or vendors
MiPharm (EUR)	9/28/2023	\$ 108,378.95	Suppliers or vendors
MiPharm (EUR)	12/1/2023	\$ 9,824.26	Suppliers or vendors
MiPharm (EUR)	12/1/2023	\$ 1,091.58	Suppliers or vendors
MiPharm (EUR)	12/18/2023	\$ 442,738.44	Suppliers or vendors
MiPharm (EUR)	12/18/2023	\$ 44,276.03	Suppliers or vendors
MiPharm (EUR) Total		\$ 716,739.09	
Mix Talent	10/4/2023	\$ 15,000.00	Suppliers or vendors
Mix Talent	10/4/2023	\$ 726.80	Suppliers or vendors
Mix Talent	10/11/2023	\$ 4,000.00	Suppliers or vendors
Mix Talent Total		\$ 19,726.80	
Moelis & Company LLC	11/8/2023	\$ 9,842.59	Suppliers or vendors
Moelis & Company LLC	12/18/2023	\$ 511,384.28	Suppliers or vendors
Moelis & Company LLC Total		\$ 521,226.87	
MTD Micromolding	12/18/2023	\$ 50,765.70	Suppliers or vendors
MTD Micromolding	12/18/2023	\$ 4,905.00	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
MTD Micromolding Total		\$ 55,670.70	
Nasdaq Inc	10/13/2023	\$ 20,000.00	Suppliers or vendors
Nasdaq Inc Total		\$ 20,000.00	
Navia Benefit Solutions	9/21/2023	\$ 6,181.52	Suppliers or vendors
Navia Benefit Solutions	9/22/2023	\$ 3,651.89	Suppliers or vendors
Navia Benefit Solutions	10/4/2023	\$ 1,569.71	Suppliers or vendors
Navia Benefit Solutions	10/10/2023	\$ 5,939.85	Other (HSA withdrawal)
Navia Benefit Solutions	10/10/2023	\$ 3,318.56	Other (FSA withdrawal)
Navia Benefit Solutions	10/10/2023	\$ 339.20	Suppliers or vendors
Navia Benefit Solutions	10/10/2023	\$ 109.00	Suppliers or vendors
Navia Benefit Solutions	10/10/2023	\$ 100.00	Suppliers or vendors
Navia Benefit Solutions	10/10/2023	\$ 0.20	Suppliers or vendors
Navia Benefit Solutions	10/20/2023	\$ 5,773.18	Other (HSA withdrawal)
Navia Benefit Solutions	10/24/2023	\$ 3,256.06	Other (FSA withdrawal)
Navia Benefit Solutions	11/2/2023	\$ 10,492.88	Suppliers or vendors
Navia Benefit Solutions	11/2/2023	\$ 1,965.32	Suppliers or vendors
Navia Benefit Solutions	11/2/2023	\$ 1,965.32	Suppliers or vendors
Navia Benefit Solutions	11/2/2023	\$ 73.22	Suppliers or vendors
Navia Benefit Solutions	11/6/2023	\$ 5,773.18	Other (HSA withdrawal)
Navia Benefit Solutions	11/7/2023	\$ 3,256.06	Other (FSA withdrawal)
Navia Benefit Solutions	11/8/2023	\$ 333.90	Suppliers or vendors
Navia Benefit Solutions	11/8/2023	\$ 109.20	Suppliers or vendors
Navia Benefit Solutions	11/8/2023	\$ 100.00	Suppliers or vendors
Navia Benefit Solutions	11/21/2023	\$ 5,273.18	Other (HSA withdrawal)
Navia Benefit Solutions	11/22/2023	\$ 2,138.76	Other (FSA withdrawal)
Navia Benefit Solutions	11/22/2023	\$ 1,569.71	Other (Cobra withdrawal)
Navia Benefit Solutions	12/5/2023	\$ 3,533.60	Other (HSA withdrawal)
Navia Benefit Solutions	12/7/2023	\$ 2,388.86	Other (FSA withdrawal)
Navia Benefit Solutions	12/8/2023	\$ 333.90	Suppliers or vendors
Navia Benefit Solutions	12/8/2023	\$ 109.20	Suppliers or vendors
Navia Benefit Solutions	12/8/2023	\$ 100.00	Suppliers or vendors
Navia Benefit Solutions	12/18/2023	\$ 1,189.57	Other (HSA withdrawal)
Navia Benefit Solutions	12/19/2023	\$ 2,343.95	Other (HSA withdrawal)
Navia Benefit Solutions Total		\$ 73,288.98	
Nelson, Tim	12/14/2023	\$ 17,500.00	Other (Board Fees)
Nelson, Tim Total		\$ 17,500.00	
Omni Agent Solutions	12/14/2023	\$ 50,000.00	Suppliers or vendors
Omni Agent Solutions Total		\$ 50,000.00	
Paul Weiss Rifkind Wharton & Garrison LLP	10/4/2023	\$ 20,000.00	Suppliers or vendors
Paul Weiss Rifkind Wharton & Garrison LLP	11/8/2023	\$ 30,303.50	Suppliers or vendors
Paul Weiss Rifkind Wharton & Garrison LLP	12/14/2023	\$ 26,696.50	Suppliers or vendors
Paul Weiss Rifkind Wharton & Garrison LLP Total		\$ 77,000.00	
PCI Pharma Services	11/2/2023	\$ 246,106.62	Suppliers or vendors
PCI Pharma Services	11/2/2023	\$ 80,836.00	Suppliers or vendors
PCI Pharma Services	12/4/2023	\$ 66,245.52	Suppliers or vendors
PCI Pharma Services	12/14/2023	\$ 246,730.86	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
PCI Pharma Services	12/14/2023	\$ 200,224.98	Suppliers or vendors
PCI Pharma Services Total		\$ 840,143.98	
Pharmaceutical Data Services (PDS)	10/4/2023	\$ 116,500.00	Suppliers or vendors
Pharmaceutical Data Services (PDS)	10/11/2023	\$ 116,500.00	Suppliers or vendors
Pharmaceutical Data Services (PDS)	11/15/2023	\$ 116,500.00	Suppliers or vendors
Pharmaceutical Data Services (PDS)	12/14/2023	\$ 116,500.00	Suppliers or vendors
Pharmaceutical Data Services (PDS) Total		\$ 466,000.00	
Phil, Inc	9/22/2023	\$ 49,407.89	Suppliers or vendors
Phil, Inc	9/28/2023	\$ 72,180.16	Suppliers or vendors
Phil, Inc	9/28/2023	\$ 72,180.16	Suppliers or vendors
Phil, Inc	9/28/2023	\$ 54,800.67	Suppliers or vendors
Phil, Inc	9/28/2023	\$ 54,800.67	Suppliers or vendors
Phil, Inc	9/28/2023	\$ 10,149.18	Suppliers or vendors
Phil, Inc	9/28/2023	\$ 10,149.18	Suppliers or vendors
Phil, Inc	9/28/2023	\$ (10,149.18)	Suppliers or vendors
Phil, Inc	9/28/2023	\$ (54,800.67)	Suppliers or vendors
Phil, Inc	9/28/2023	\$ (72,180.16)	Suppliers or vendors
Phil, Inc	10/4/2023	\$ 63,534.84	Suppliers or vendors
Phil, Inc	10/4/2023	\$ 270.00	Suppliers or vendors
Phil, Inc	10/11/2023	\$ 9,351.30	Suppliers or vendors
Phil, Inc	10/18/2023	\$ 28,013.90	Suppliers or vendors
Phil, Inc	10/25/2023	\$ 45,699.37	Suppliers or vendors
Phil, Inc	11/1/2023	\$ 54,133.54	Suppliers or vendors
Phil, Inc	11/1/2023	\$ 42,917.98	Suppliers or vendors
Phil, Inc	11/1/2023	\$ 7,371.52	Suppliers or vendors
Phil, Inc	11/8/2023	\$ 65,271.00	Suppliers or vendors
Phil, Inc	11/8/2023	\$ 37,325.20	Suppliers or vendors
Phil, Inc	11/8/2023	\$ 1,864.26	Suppliers or vendors
Phil, Inc	11/15/2023	\$ 47,573.63	Suppliers or vendors
Phil, Inc	11/21/2023	\$ 46,676.50	Suppliers or vendors
Phil, Inc	11/30/2023	\$ 62,286.25	Suppliers or vendors
Phil, Inc	11/30/2023	\$ 35,520.94	Suppliers or vendors
Phil, Inc	11/30/2023	\$ 12,446.12	Suppliers or vendors
Phil, Inc	12/14/2023	\$ 39,109.46	Suppliers or vendors
Phil, Inc	12/14/2023	\$ 25,192.51	Suppliers or vendors
Phil, Inc	12/18/2023	\$ 8,706.94	Suppliers or vendors
Phil, Inc	12/19/2023	\$ 68,120.49	Suppliers or vendors
Phil, Inc	12/19/2023	\$ 59,135.15	Suppliers or vendors
Phil, Inc Total		\$ 947,058.80	
PPD Development	11/8/2023	\$ 9,157.50	Suppliers or vendors
PPD Development	11/8/2023	\$ 1,610.00	Suppliers or vendors
PPD Development	11/15/2023	\$ 17,750.00	Suppliers or vendors
PPD Development	11/30/2023	\$ 10,956.00	Suppliers or vendors
PPD Development	11/30/2023	\$ 9,157.50	Suppliers or vendors
PPD Development Total		\$ 48,631.00	
Premier Consulting (Camargo)	10/4/2023	\$ 5,850.00	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Premier Consulting (Camargo)	10/4/2023	\$ 3,507.50	Suppliers or vendors
Premier Consulting (Camargo)	10/4/2023	\$ 600.00	Suppliers or vendors
Premier Consulting (Camargo) Total		\$ 9,957.50	
Premier Research Consulting	11/8/2023	\$ 2,625.00	Suppliers or vendors
Premier Research Consulting	11/8/2023	\$ 1,350.00	Suppliers or vendors
Premier Research Consulting	11/8/2023	\$ 600.00	Suppliers or vendors
Premier Research Consulting	12/18/2023	\$ 3,240.00	Suppliers or vendors
Premier Research Consulting	12/18/2023	\$ 2,230.00	Suppliers or vendors
Premier Research Consulting	12/18/2023	\$ 1,855.00	Suppliers or vendors
Premier Research Consulting	12/18/2023	\$ 787.50	Suppliers or vendors
Premier Research Consulting	12/18/2023	\$ 300.00	Suppliers or vendors
Premier Research Consulting Total		\$ 12,987.50	
PSKW, LLC (ConnectiveRx)	9/22/2023	\$ 196,385.71	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	10/4/2023	\$ 8,150.00	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	10/4/2023	\$ 1,877.50	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/1/2023	\$ 163,917.72	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/1/2023	\$ 158,427.04	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/1/2023	\$ 8,150.00	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/1/2023	\$ 1,758.75	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/21/2023	\$ 169,920.04	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/21/2023	\$ 128,142.63	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/30/2023	\$ 8,150.00	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	11/30/2023	\$ 1,668.75	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	12/4/2023	\$ 154,544.74	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	12/14/2023	\$ 97,729.48	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	12/14/2023	\$ 8,150.00	Suppliers or vendors
PSKW, LLC (ConnectiveRx)	12/14/2023	\$ 1,511.25	Suppliers or vendors
PSKW, LLC (ConnectiveRx) Total		\$ 1,108,483.61	
QPharma	10/4/2023	\$ 6,816.25	Suppliers or vendors
QPharma	10/4/2023	\$ 6,490.00	Suppliers or vendors
QPharma	10/4/2023	\$ 2,410.95	Suppliers or vendors
QPharma	10/4/2023	\$ 2,388.59	Suppliers or vendors
QPharma	10/4/2023	\$ 1,505.00	Suppliers or vendors
QPharma	10/4/2023	\$ 1,118.84	Suppliers or vendors
QPharma	11/8/2023	\$ 6,560.00	Suppliers or vendors
QPharma	11/30/2023	\$ 5,101.75	Suppliers or vendors
QPharma	11/30/2023	\$ 1,142.50	Suppliers or vendors
QPharma	12/4/2023	\$ 6,000.00	Suppliers or vendors
QPharma	12/4/2023	\$ 5,351.33	Suppliers or vendors
QPharma	12/4/2023	\$ 1,205.00	Suppliers or vendors
QPharma Total		\$ 46,090.21	
Resources Global Professionals	10/11/2023	\$ 2,250.00	Suppliers or vendors
Resources Global Professionals	10/11/2023	\$ 1,450.00	Suppliers or vendors
Resources Global Professionals	10/11/2023	\$ 650.00	Suppliers or vendors
Resources Global Professionals	11/30/2023	\$ 2,650.00	Suppliers or vendors
Resources Global Professionals	12/4/2023	\$ 3,050.00	Suppliers or vendors

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Resources Global Professionals Total		\$ 10,050.00	
Robert Half	9/22/2023	\$ 2,156.25	Suppliers or vendors
Robert Half	10/4/2023	\$ 2,001.00	Suppliers or vendors
Robert Half	10/4/2023	\$ 1,828.50	Suppliers or vendors
Robert Half	10/11/2023	\$ 2,070.00	Suppliers or vendors
Robert Half	10/18/2023	\$ 2,070.00	Suppliers or vendors
Robert Half	10/25/2023	\$ 2,052.75	Suppliers or vendors
Robert Half	11/8/2023	\$ 2,001.00	Suppliers or vendors
Robert Half	11/8/2023	\$ 2,001.00	Suppliers or vendors
Robert Half	11/15/2023	\$ 2,070.00	Suppliers or vendors
Robert Half	11/21/2023	\$ 2,070.00	Suppliers or vendors
Robert Half	12/1/2023	\$ 1,811.25	Suppliers or vendors
Robert Half	12/14/2023	\$ 2,070.00	Suppliers or vendors
Robert Half	12/14/2023	\$ 2,001.00	Suppliers or vendors
Robert Half Total		\$ 26,202.75	
SciLucent	10/4/2023	\$ 6,793.75	Suppliers or vendors
SciLucent	10/11/2023	\$ 6,428.75	Suppliers or vendors
SciLucent	11/8/2023	\$ 180.00	Suppliers or vendors
SciLucent Total		\$ 13,402.50	
Sedulo Group	10/4/2023	\$ 13,875.00	Suppliers or vendors
Sedulo Group	10/4/2023	\$ 13,875.00	Suppliers or vendors
Sedulo Group Total		\$ 27,750.00	
SHOP-PR LLC_TWELVENOTE	10/4/2023	\$ 150,000.00	Suppliers or vendors
SHOP-PR LLC_TWELVENOTE	10/11/2023	\$ 32,813.26	Suppliers or vendors
SHOP-PR LLC_TWELVENOTE Total		\$ 182,813.26	
Sidley Austin LLP	9/22/2023	\$ (179,966.36)	Suppliers or vendors
Sidley Austin LLP	11/8/2023	\$ 25,000.00	Suppliers or vendors
Sidley Austin LLP	11/15/2023	\$ 25,000.00	Suppliers or vendors
Sidley Austin LLP	11/21/2023	\$ 275,000.00	Suppliers or vendors
Sidley Austin LLP	12/4/2023	\$ 400,000.00	Suppliers or vendors
Sidley Austin LLP	12/18/2023	\$ 100,000.00	Suppliers or vendors
Sidley Austin LLP Total		\$ 645,033.64	
Stern IR	10/4/2023	\$ 19,483.68	Suppliers or vendors
Stern IR	10/11/2023	\$ 37,993.18	Suppliers or vendors
Stern IR Total		\$ 57,476.86	
Sullivan & Cromwell	12/18/2023	\$ 517,657.18	Suppliers or vendors
Sullivan & Cromwell Total		\$ 517,657.18	
Symphony Health	10/11/2023	\$ 217,568.00	Suppliers or vendors
Symphony Health	10/11/2023	\$ 47,224.75	Suppliers or vendors
Symphony Health Total		\$ 264,792.75	
Teneo Capital LLC	10/11/2023	\$ 71,115.00	Suppliers or vendors
Teneo Capital LLC	11/9/2023	\$ 78,660.00	Suppliers or vendors
Teneo Capital LLC	11/21/2023	\$ 257,500.00	Suppliers or vendors
Teneo Capital LLC	12/4/2023	\$ 100,000.00	Suppliers or vendors
Teneo Capital LLC	12/18/2023	\$ 40,000.00	Suppliers or vendors
Teneo Capital LLC Total		\$ 547,275.00	

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
TrnDigital, LLC	10/4/2023	\$ 39,828.92	Suppliers or vendors
TrnDigital, LLC	10/4/2023	\$ 13,230.00	Suppliers or vendors
TrnDigital, LLC	10/4/2023	\$ 2,424.40	Suppliers or vendors
TrnDigital, LLC	10/11/2023	\$ 14,039.35	Suppliers or vendors
TrnDigital, LLC	11/8/2023	\$ 13,230.00	Suppliers or vendors
TrnDigital, LLC	11/8/2023	\$ 2,424.40	Suppliers or vendors
TrnDigital, LLC	11/15/2023	\$ 32,637.86	Suppliers or vendors
TrnDigital, LLC	11/15/2023	\$ 14,051.14	Suppliers or vendors
TrnDigital, LLC	11/30/2023	\$ 13,230.00	Suppliers or vendors
TrnDigital, LLC	11/30/2023	\$ 2,424.40	Suppliers or vendors
TrnDigital, LLC	12/4/2023	\$ 19,673.56	Suppliers or vendors
TrnDigital, LLC	12/14/2023	\$ 14,099.89	Suppliers or vendors
TrnDigital, LLC	12/14/2023	\$ 13,230.00	Suppliers or vendors
TrnDigital, LLC Total		\$ 194,523.92	
Trust.Med	12/4/2023	\$ 22,500.00	Suppliers or vendors
Trust.Med Total		\$ 22,500.00	
Two Labs Holdings LLC	10/4/2023	\$ 9,000.00	Suppliers or vendors
Two Labs Holdings LLC	10/4/2023	\$ 8,000.00	Suppliers or vendors
Two Labs Holdings LLC	10/11/2023	\$ 9,000.00	Suppliers or vendors
Two Labs Holdings LLC	11/30/2023	\$ 9,000.00	Suppliers or vendors
Two Labs Holdings LLC Total		\$ 35,000.00	
Uppsala Monitoring Centre (SEK)	10/4/2023	\$ 10,554.88	Suppliers or vendors
Uppsala Monitoring Centre (SEK) Total		\$ 10,554.88	
Veeva	10/4/2023	\$ 4,950.00	Suppliers or vendors
Veeva	11/8/2023	\$ 4,950.00	Suppliers or vendors
Veeva	12/4/2023	\$ 4,950.00	Suppliers or vendors
Veeva Total		\$ 14,850.00	
Verizon Wireless	11/3/2023	\$ 2,919.94	Suppliers or vendors
Verizon Wireless	11/15/2023	\$ 2,931.38	Suppliers or vendors
Verizon Wireless	12/14/2023	\$ 2,938.90	Suppliers or vendors
Verizon Wireless Total		\$ 8,790.22	
Wilfong, Diane	12/14/2023	\$ 16,250.00	Other (Board Fees)
Wilfong, Diane Total		\$ 16,250.00	
Withum	11/6/2023	\$ 10,500.00	Suppliers or vendors
Withum Total		\$ 10,500.00	
Woodruff-Sawyer & Co	9/25/2023	\$ 688.00	Suppliers or vendors
Woodruff-Sawyer & Co	9/25/2023	\$ (688.00)	Suppliers or vendors
Woodruff-Sawyer & Co	10/4/2023	\$ 1,000.00	Suppliers or vendors
Woodruff-Sawyer & Co	10/4/2023	\$ 655.00	Suppliers or vendors
Woodruff-Sawyer & Co	10/4/2023	\$ (1,000.00)	Suppliers or vendors
Woodruff-Sawyer & Co	11/15/2023	\$ 616.00	Suppliers or vendors
Woodruff-Sawyer & Co	12/4/2023	\$ 103,026.99	Suppliers or vendors
Woodruff-Sawyer & Co	12/4/2023	\$ 31,000.00	Suppliers or vendors
Woodruff-Sawyer & Co	12/4/2023	\$ 3,430.00	Suppliers or vendors
Woodruff-Sawyer & Co	12/4/2023	\$ 1,000.00	Suppliers or vendors
Woodruff-Sawyer & Co Total		\$ 139,727.99	

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 3. Certain payments or transfers to creditors within 90 days before filing this case

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer
Zinc Health Services	10/10/2023	\$ 307,345.82	Other (rebates)
Zinc Health Services	10/10/2023	\$ 59,867.81	Other (rebates)
Zinc Health Services	11/8/2023	\$ 292,611.70	Other (rebates)
Zinc Health Services	11/8/2023	\$ 57,572.09	Other (rebates)
Zinc Health Services	12/4/2023	\$ 244,932.97	Other (rebates)
Zinc Health Services	12/4/2023	\$ 47,353.92	Other (rebates)
Zinc Health Services	12/18/2023	\$ 195,524.37	Other (rebates)
Zinc Health Services	12/18/2023	\$ 37,854.57	Other (rebates)
Zinc Health Services Total		\$ 1,243,063.25	
Grand Total		\$ 18,302,574.95	

STATEMENT OF FINANCIAL AFFAIRS

**EXHIBIT
PART 2, QUESTION 4**

**PAYMENTS OR OTHER TRANSFERS OF PROPERTY MADE
WITHIN 1 YEAR BEFORE FILING THIS CASE THAT
BENEFITTED ANY INSIDER**

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA4. Payments or other transfers of property made within 1 year before filing this case that benefited any insider

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
5AM Ventures (David Allison)	12/30/2022	\$20,625.00	Board Fees	Director
5AM Ventures (David Allison)	3/30/2023	\$13,750.00	Board Fees	Director
5AM Ventures (David Allison) Total		\$34,375.00		
Allison, David	3/30/2023	\$6,875.00	Board Fees	Director
Allison, David	6/30/2023	\$20,625.00	Board Fees	Director
Allison, David	7/19/2023	\$20,625.00	Board Fees	Director
Allison, David	12/14/2023	\$20,625.00	Board Fees	Director
Allison, David Total		\$68,750.00		
Cline, Darren	6/30/2023	\$10,833.00	Board Fees	Director
Cline, Darren	7/19/2023	\$12,500.00	Board Fees	Director
Cline, Darren	12/14/2023	\$12,500.00	Board Fees	Director
Cline, Darren Total		\$35,833.00		
KKR Iris Investors, LLC (Ali Satvat)	12/30/2022	\$13,750.00	Board Fees	Director
KKR Iris Investors, LLC (Ali Satvat)	3/30/2023	\$13,750.00	Board Fees	Director
KKR Iris Investors, LLC (Ali Satvat)	6/30/2023	\$13,750.00	Board Fees	Director
KKR Iris Investors, LLC (Ali Satvat)	7/19/2023	\$13,750.00	Board Fees	Director
KKR Iris Investors, LLC (Ali Satvat)	12/14/2023	\$13,750.00	Board Fees	Director
KKR Iris Investors, LLC (Ali Satvat)		\$68,750.00		
Nelson, Tim	12/28/2022	\$34,500.00	Board Fees	Director
Nelson, Tim	3/30/2023	\$15,000.00	Board Fees	Director
Nelson, Tim	4/28/2023	\$655.28	Expense Reimbursement	Director
Nelson, Tim	6/30/2023	\$17,222.00	Board Fees	Director
Nelson, Tim	7/19/2023	\$17,500.00	Board Fees	Director
Nelson, Tim	12/14/2023	\$17,500.00	Board Fees	Director
Nelson, Tim Total		\$102,377.28		
Parker, Stewart	12/30/2022	\$15,000.00	Board Fees	Director
Parker, Stewart	2/16/2023	\$1,191.86	Expense Reimbursement	Director
Parker, Stewart	3/30/2023	\$15,000.00	Board Fees	Director
Parker, Stewart	5/25/2023	\$645.30	Expense Reimbursement	Director
Parker, Stewart	6/30/2023	\$1,667.00	Expense Reimbursement	Director
Parker, Stewart Total		\$33,504.16		
Shrewsbury, Stephen	12/20/2022	\$159.37	Expense Reimbursement	Officer
Shrewsbury, Stephen	1/24/2023	\$300.43	Expense Reimbursement	Officer
Shrewsbury, Stephen	2/21/2023	\$118.17	Expense Reimbursement	Officer
Shrewsbury, Stephen	4/19/2023	\$462.44	Expense Reimbursement	Officer
Shrewsbury, Stephen	5/3/2023	\$12,000.00	Consulting Fees	Former Officer
Shrewsbury, Stephen	6/21/2023	\$2,309.44	Consulting Fees	Former Officer
Shrewsbury, Stephen	8/2/2023	\$3,690.00	Consulting Fees	Former Officer
Shrewsbury, Stephen Total		\$19,039.85		
VIVO Capital, LLC (Mahendra Shah)	12/28/2022	\$15,625.00	Board Fees	Director

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA4. Payments or other transfers of property made within 1 year before filing this case that benefited any insider

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
VIVO Capital, LLC (Mahendra Shah)	3/30/2023	\$15,625.00	Board Fees	Director
VIVO Capital, LLC (Mahendra Shah)	6/21/2023	\$1,734.32	Expense Reimbursement	Director
VIVO Capital, LLC (Mahendra Shah)	6/21/2023	\$387.54	Expense Reimbursement	Director
VIVO Capital, LLC (Mahendra Shah)	6/30/2023	\$15,625.00	Board Fees	Director
VIVO Capital, LLC (Mahendra Shah)	7/19/2023	\$15,625.00	Board Fees	Director
VIVO Capital, LLC (Mahendra Shah)		\$64,621.86		
Wilfong, Diane	12/30/2022	\$16,250.00	Board Fees	Director
Wilfong, Diane	3/30/2023	\$16,250.00	Board Fees	Director
Wilfong, Diane	5/3/2023	\$1,353.57	Expense Reimbursement	Director
Wilfong, Diane	6/30/2023	\$16,250.00	Board Fees	Director
Wilfong, Diane	7/19/2023	\$16,250.00	Board Fees	Director
Wilfong, Diane	12/14/2023	\$16,250.00	Board Fees	Director
Wilfong, Diane	12/9/2022	\$1,003.41	Expense Reimbursement	Director
Wilfong, Diane Total		\$83,606.98		
Grand Total		\$510,858.13		

STATEMENT OF FINANCIAL AFFAIRS

**EXHIBIT
PART 5, QUESTION 10**

**ALL LOSSES FROM FIRE, THEFT, OR OTHER CASUALTY
WITHIN 1 YEAR BEFORE FILING THIS CASE**



Detail Loss Report

Losses From: 01/16/2021 To 01/16/2024

Claimant	Adj Off	FP	Claim Number	Accident Date	Notice Date	Close Date	O/C	Total	Claim	Medical	Expense
Policy Year: 2022											
Line of Insurance: AL - AUTOMOBILE											
/EMKAY INCORPORATED	133	AD	FJY3505	12/29/2022	12/29/2022	03/22/2023	C				
LEFT SIDE AND RIGHT FRONT DOOR							Inc:	\$2,002.00	\$2,002.00	\$0.00	\$0.00
							Pd:	\$2,002.13	\$2,002.13	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
/IMPEL PHARMACEUTICALS IN	042	AD	FWY6043	05/21/2023	06/08/2023	07/20/2023	C				
DRIVER BELIEVES ROCK STRUCK SUNROOF CAUSING CRACK TO FORM							Inc:	\$56.00	\$56.00	\$0.00	\$0.00
							Pd:	\$56.04	\$56.04	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
/IMPEL PHARMACEUTICALS IN	007	AD	FXH6786	05/31/2023	05/31/2023	08/01/2023	C				
DRIVER WAS BACKING OUT OF A PARKING SPACE AND SHE COULDN'T SEE AND STRUCK THE WOODEN POLE.							Inc:	\$1,628.00	\$1,628.00	\$0.00	\$0.00
							Pd:	\$1,628.34	\$1,628.34	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
/IMPEL PHARMACEUTICALS IN	028	AD	FYC4679	05/29/2023	05/30/2023	06/15/2023	C				
MY VOLVO WAS BROKEN INTO THIS MORNING IN CHICAGO AND MY WALLET WAS STOLEN. I PARKED BY THE LAKE TO EXERCISE AND WHEN I RETURNED MY FRONT PASSENGER							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
/IMPEL PHARMACEUTICALS IN	026	AD	FZJ9887	10/17/2023	11/17/2023	01/11/2024	C				
VEHICLE #1 WAS PARALLEL PARKING AND STRUCK A PARKING METER WHICH CAUSED DAMAGE TO THE RIGHT REAR OF VEHICLE #1.							Inc:	\$3,452.00	\$3,452.00	\$0.00	\$0.00
							Pd:	\$3,452.35	\$3,452.35	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
/IMPEL PHARMACEUTICALS IN	028	AD	F0F1199	08/31/2023	09/01/2023	09/12/2023	C				
VEH 1 WAS PARKED / UNOCCUPIED. WHEN THE DRIVER WENT TO HIS VEHICLE, IT WAS NOTICED THAT THE DRIVER-SIDE REAR WINDOW WAS SHATTERED. A COMPUTER BAG WAS STOLEN FROM THE BACK SEAT							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
/IMPEL PHARMACEUTICALS IN	039	AD	F0L6156	06/13/2023	06/13/2023	08/17/2023	C				
HAIL							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
[REDACTED]	026	AD	FZJ0594	07/16/2023	07/17/2023	09/14/2023	C				
DRIVER'S WIFE JILL WAS DRIVING IN THE PARKING LOT AT CHURCH AND PULLED INTO A PARKING SPACE; STRIKING A PARKED VEHICLE							Inc:	\$8,651.00	\$8,651.00	\$0.00	\$0.00
							Pd:	\$8,651.06	\$8,651.06	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
[REDACTED]	028	AD	FWT7992	02/13/2023	02/13/2023	03/10/2023	C				
VEH1 AND VEH2 BACKING OUT OF PARKING SPOTS AT SAME TIME AND REAR-ENDED EACH OTHER							Inc:	\$364.00	\$364.00	\$0.00	\$0.00
							Pd:	\$364.41	\$364.41	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00



Detail Loss Report

Losses From: 01/16/2021 To 01/16/2024

Claimant	Adj Off	FP	Claim Number	Accident Date	Notice Date	Close Date	O/C	Total	Claim	Medical	Expense
Policy Year: 2022											
Line of Insurance: AL - AUTOMOBILE											
	039	AD	F0J5582	05/11/2023	05/11/2023	09/10/2023	C				
VEH1 WAS IN THE FAR LEFT TURNING LANE WHEN VEH2 CAME DARTING OUT OF A GAS STATION PARKING LOT.								Inc:	\$0.00	\$0.00	\$0.00
VEH2 CROSSED 3 LANES OF TRAFFIC STRIKING VEH1 IN THE FRONT PASSENGER SIDE WHEEL								Pd:	\$0.00	\$0.00	\$0.00
								O/S:	\$0.00	\$0.00	\$0.00
	007	PP	FZD1908	09/06/2023	09/06/2023	12/27/2023	C				
VEH 2 REAR ENDED VEH 1 AT A HIGH SPEED.								Inc:	\$34.00	\$34.00	\$0.00
								Pd:	\$34.45	\$34.45	\$0.00
								O/S:	\$0.00	\$0.00	\$0.00
	028	PP	FWY4915	05/15/2023	05/15/2023	06/02/2023	C				
VEH1 WAS IN BUMPER TO BUMPER WHEN VEH2 REAR-ENDED VEH1								Inc:	\$2,953.00	\$2,953.00	\$0.00
								Pd:	\$2,952.73	\$2,952.73	\$0.00
								O/S:	\$0.00	\$0.00	\$0.00
	003	AD	FQG9360	07/06/2023	07/07/2023	07/25/2023	C				
VEH1 WAS EXITING PARKING LOT AND VEH2 WAS BACKING UP FROM A PARKING SPACE AND BACKED INTO VEH1								Inc:	\$0.00	\$0.00	\$0.00
								Pd:	\$0.00	\$0.00	\$0.00
								O/S:	\$0.00	\$0.00	\$0.00
	028	AD	F0F2148	09/16/2023	09/18/2023		O				
STOP INSURED WAS REAR ENDED BY 3RD PARTY WHO WAS LOOKING DOWN AT HIS PHONE.								Inc:	\$6,443.00	\$6,443.00	\$0.00
								Pd:	\$5,442.23	\$5,442.23	\$0.00
								O/S:	\$1,000.77	\$1,000.77	\$0.00
	133	AD	FJY4771	06/04/2023	06/05/2023	10/25/2023	O				
VEHICLES #1 AND #2 WERE BACKING OUT OF PARKING SPACES ACROSS FROM EACH OTHER AT 2002 WASHINGTON ST AND BACKED INTO EACH OTHER.								Inc:	\$5,392.00	\$5,392.00	\$0.00
								Pd:	\$5,391.20	\$5,391.20	\$0.00
								O/S:	\$0.00	\$0.00	\$0.00
UNK UNK	007	AD	FXH5958	05/15/2023	05/16/2023	06/20/2023	C				
VEH2 STRUCK ROAD A TIRE TREAD WHICH THEN PUSHED IT INTO THE FRONT OF VEH1. VEH1 RAN OVER THE TIRE TREAD CAUSING DAMAGE TO THE FRONT BUMPER								Inc:	\$522.00	\$522.00	\$0.00
								Pd:	\$522.16	\$522.16	\$0.00
								O/S:	\$0.00	\$0.00	\$0.00
Subtotals for Line of Insurance : AL								Inc:	\$31,497.00	\$31,497.00	\$0.00
Total Claim Count: 16								Pd:	\$30,497.10	\$30,497.10	\$0.00
								O/S:	\$999.90	\$999.90	\$0.00



Detail Loss Report

Losses From: 01/16/2021 To 01/16/2024

Claimant	Adj Off	FP	Claim Number	Accident Date	Notice Date	Close Date	O/C	Total	Claim	Medical	Expense
Policy Year: 2022											
Subtotals for Policy Year : 2022											
Total Claim Count: 16							Inc:	\$31,497.00	\$31,497.00	\$0.00	\$0.00
							Pd:	\$30,497.10	\$30,497.10	\$0.00	\$0.00
							O/S:	\$999.90	\$999.90	\$0.00	\$0.00
Policy Year: 2023											
Line of Insurance: AL - AUTOMOBILE											
	028	AD	F0F8922	01/04/2024	01/05/2024		O				
VEHICLE 1 WAS BEHIND VEHICLE 2. WHEN THE LIGHT TURNED GREEN, TRAFFIC MOVED FORWARD THEN ABRUPTLY STOPPED AS TRAFFIC WAS HEAVY. VEHICLE 1 THEN REAR ENDED VEHICLE 2.							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
	028	AD	F0F8934	01/04/2024	01/05/2024		O				
CLAIMANT ON A ROAD THAT HAS LOTS OF RED LIGHTS AND TRAFFIC WAS STOPPING AND THE CLAIMANT STOPPED AND WAS REAR ENDED BY THE INSURED							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
	186	AD	FEM9486	11/10/2023	11/13/2023	01/09/2024	C				
A GENTLEMAN (DRIVER OF VEH 2) CAME INSIDE AND ASKED IF THE WHITE VOLVO PARKED OUT FRONT WAS OURS, AS HE HAD JUST BACKED INTO IT. HE SAID HE BACKING OUT OF HIS SPOT, AND WHEN HE WAS BACKING UP, HE HIT THE REAR DRIVER SIDE DOOR							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
	028	AD	F0F8441	12/17/2023	12/26/2023		O				
VEH 1 WAS BACKING OUT OF THE DRIVEWAY AND VEH 2 HAD PARKED HIS TRUCK DIRECTLY LINED UP WITH MY DRIVEWAY ON THE OTHER SIDE OF THE STREET. VEH 1 BACKED INTO IT BECAUSE THERE WERE MINIMAL STREET LIGHTS AND IT COULD NOT BE SEEN.							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
Subtotals for Line of Insurance : AL											
Total Claim Count: 4							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00
Subtotals for Policy Year : 2023											
Total Claim Count: 4							Inc:	\$0.00	\$0.00	\$0.00	\$0.00
							Pd:	\$0.00	\$0.00	\$0.00	\$0.00
							O/S:	\$0.00	\$0.00	\$0.00	\$0.00



Detail Loss Report									Losses From: 01/16/2021 To 01/16/2024		
Claimant	Adj Off	FP	Claim Number	Accident Date	Notice Date	Close Date	O/C	Total	Claim	Medical	Expense
Report Grand Totals							Inc:	\$31,497.00	\$31,497.00	\$0.00	\$0.00
Total Claim Count: 20							Pd:	\$30,497.10	\$30,497.10	\$0.00	\$0.00
							O/S:	\$999.90	\$999.90	\$0.00	\$0.00



Detail Loss Report			Losses From: 01/16/2021 To 01/16/2024	
Report Parameters				
Report Name: Detail Loss Losses From: 01/16/2021 To 01/16/2024			Policy Number(s): 9T026567	
Sorts				
Sort Name		Sort Label	Subtotal	Page Break
1. Policy Year		Policy Year	Y	N
2. Line of Insurance		Line of Insurance	Y	N
Limiting Statements				
Large Loss Limiting				
Drill Down Limiting Criteria				

STATEMENT OF FINANCIAL AFFAIRS

EXHIBIT

PART 10, QUESTION 20

OFF-PREMISES STORAGE

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 20: Off-premises Storage

Facility Name and Address	Names of Anyone with Access to It	Description of the Contents	Does Debtor Still Have It?
A-1 Self Storage , 2245 Hotel Circle South San Diego, CA 92108		Trudhesa Product Samples	Yes
Affordable Storage Guys Springfield , 3715 S Grand Slam Ave Sioux Falls, SD 57110		Trudhesa Product Samples	Yes
All Around Storage , 1350 SSE Loop 7 Athens, TX 76501		Trudhesa Product Samples	Yes
Chenal Highway Mini Storage , 24300 Chenal Parkway Little Rock, AR 72223		Trudhesa Product Samples	Yes
Citadel Self Storage , 133 N Locust Hill Dr Lexington, KY 40509		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 1101 North St Anoka, MN 55303		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 11820 W Olympic Blvd Los Angeles, CA 90064		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 3195 S Congress Ave Delray Beach, FL 33445		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 4 Lotus Blvd Hackettstown, NJ 07840		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 4 Research PI Rockville, MD 20850		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 5361 Nottingham Rd White Marsh, MD 21236		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 6801 Engle Rd Middleburg Heights, OH 44130		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 7949 Broad River Rd Irmo, SC 29063		Trudhesa Product Samples	Yes
Extra Space Storage, 12330 US 15 501 N Chapel Hill, NC 27517		Trudhesa Product Samples	Yes
Extra Space Storage, 2855 N Houston Levee Rd Cordova, TN 38016		Trudhesa Product Samples	Yes
Extra Space Storage, 430 Bishop St NW Atlanta, GA 30318		Trudhesa Product Samples	Yes
Extra Space Storage, 4690 Industrial St Simi Valley, CA 93063		Trudhesa Product Samples	Yes
Extra Space Storage, 7770 Folsom-Auburn Rd Folsom, CA 95630		Trudhesa Product Samples	Yes
Extra Space Storage, 8627 Middlebrook Pike Knoxville, TN 37923		Trudhesa Product Samples	Yes
Extra Space Storage, 871 Willow St Redwood City, CA 94063		Trudhesa Product Samples	Yes
Extra Space Storage, 8890 SW 72nd St Miami, FL 33173		Trudhesa Product Samples	Yes
Guardian Self Storage , 367 High Pointe Drive Seven Fields, PA 16046		Trudhesa Product Samples	Yes
Hawthorn Storage , 100 W. Terra Cotta Crystal Lake, IL 60014		Trudhesa Product Samples	Yes
iStorage / Hanover Holdings Ltd , 20772 Hall Road Clinton Township, MI 48038		Trudhesa Product Samples	Yes
Life Storage, 104 Bennett Road Camillus, NY 13031		Trudhesa Product Samples	Yes
Life Storage, 10760 N 116th St Scottsdale, AZ 85259		Trudhesa Product Samples	Yes
Life Storage, 1844 N Belcher Rd Clearwater, FL 33765		Trudhesa Product Samples	Yes
Life Storage, 24 Sterling Place Amityville, NY 11701		Trudhesa Product Samples	Yes
Life Storage, 2661 Veterans Memorial Pkwy Saint Charles, MO 63303		Trudhesa Product Samples	Yes
Life Storage, 3626 N Broadway St Chicago, IL 60613		Trudhesa Product Samples	Yes
Life Storage, 400 Kenmore Ave Kenmore, NY 14223		Trudhesa Product Samples	Yes
Life Storage, 4959 Manchester Ave Saint Louis, MO 63110		Trudhesa Product Samples	Yes
Life Storage, 6350 Nolensville Pike Nashville, TN 37211		Trudhesa Product Samples	Yes
Life Storage, 8625 Spring Cypress Spring, TX 77379		Trudhesa Product Samples	Yes
McDowell Mountain Community Storage , 10101 E. McDowell Mountain Ranch Rd Scottsdale, AZ 85255		Trudhesa Product Samples	Yes
Metro Self Storage , 3952 N. Providence Rd. Newtown Square, PA 19073		Trudhesa Product Samples	Yes
Prime Storage Group , 701 Bleachery Blvd Asheville, NC 28801		Trudhesa Product Samples	Yes
Public Storage , 7533 Woodcutter Dr. Powell, OH 43065		Trudhesa Product Samples	Yes
Scottsdale Storage Solutions , 6900 E. Thomas Rd Scottsdale, AZ 85251		Trudhesa Product Samples	Yes
SecurCare Self Storage , 6978 Central Blvd Zionsville, IN 46077		Trudhesa Product Samples	Yes
StorageMart , 1720 Grand Blvd Kansas City, MO 64108		Trudhesa Product Samples	Yes
Uncle Bill's Self Storage , 906 Apple St Normal, IL 61761		Trudhesa Product Samples	Yes
Wildcat Self Storage , 5828 Harrison Blvd Ogden, UT 84403		Trudhesa Product Samples	Yes
CubeSmart Self Storage, 1201 N Highway 377 Roanoke, TX 76262		Trudhesa Product Samples	Yes
Extra Space Storage, 1730 S 8th St Colorado Springs, CO 80905		Trudhesa Product Samples	Yes
Cardinal Health 105, LLC - 501 Mason Road, Suite 200, La Vergne, Tennessee, 37086		Finished Good inventory of Trudhesa	Yes
Cubework - 218 Machlin Court, Walnut CA 91789 - Unit B07.		Raw Material inventory	Yes
Freudenberg Medical - 5050 Rivergrade Rd, Baldwin Park, CA 91706		Raw Material inventory	Yes
PCI Pharma Services, 4545 Assembly Drive Rockford, IL 61109 USA		Sub Assembly inventory	Yes
MIPharm S.p.A - Via B Quaranta 12, I-20141 Milan, Italy		Bulk API inventory	Yes

STATEMENT OF FINANCIAL AFFAIRS

**EXHIBIT
PART 2, QUESTION 30**

**PAYMENTS, DISTRIBUTIONS OR WITHDRAWALS
CREDITED OR GIVEN TO INSIDERS**

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 30. Payments, distributions, or withdrawals credited or given to insiders

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
Adams, Adrian	12/20/2022	\$26,041.75	Wages	CEO, Chairman
Adams, Adrian	1/5/2023	\$26,041.75	Wages	CEO, Chairman
Adams, Adrian	1/20/2023	\$26,041.75	Wages	CEO, Chairman
Adams, Adrian	2/3/2023	\$26,041.75	Wages	CEO, Chairman
Adams, Adrian	2/14/2023	\$33,333.00	ISO Options Granted, Amount Vested at Termination	CEO, Chairman
Adams, Adrian	2/17/2023	\$26,041.75	Wages	CEO, Chairman
Adams, Adrian	2/17/2023	\$206,250.66	Bonus	CEO, Chairman
Adams, Adrian	3/3/2023	\$30,208.43	Wages	CEO, Chairman
Adams, Adrian	3/20/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	4/5/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	4/20/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	5/5/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	5/19/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	6/5/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	6/20/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	7/5/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	7/20/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	8/4/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	8/18/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	9/5/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	9/20/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	10/5/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	10/20/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	11/3/2023	\$27,083.42	Wages	CEO, Chairman
Adams, Adrian	11/20/2023	\$20,000.00	Wages	CEO, Chairman
Adams, Adrian Total		\$853,335.56		
Hoekman, John D	12/20/2022	\$17,681.25	Wages	CTO, CDO
Hoekman, John D	1/5/2023	\$17,681.25	Wages	CTO, CDO
Hoekman, John D	1/20/2023	\$17,681.25	Wages	CTO, CDO
Hoekman, John D	2/3/2023	\$17,681.25	Wages	CTO, CDO
Hoekman, John D	2/14/2023	\$8,854.00	ISO Options Granted, Amount Vested as of 1/8/24	CTO, CDO
Hoekman, John D	2/17/2023	\$17,681.25	Wages	CTO, CDO
Hoekman, John D	2/17/2023	\$107,148.38	Bonus	CTO, CDO
Hoekman, John D	3/3/2023	\$20,510.25	Wages	CTO, CDO
Hoekman, John D	3/20/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	4/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	4/20/2023	\$18,388.50	Wages	CTO, CDO

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 30. Payments, distributions, or withdrawals credited or given to insiders

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
Hoekman, John D	5/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	5/19/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	6/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	6/20/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	7/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	7/20/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	8/4/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	8/18/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	9/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	9/20/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	9/20/2023	\$88,265.00	Advanced Severance	CTO, CDO
Hoekman, John D	10/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	10/20/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	11/3/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	11/20/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	12/5/2023	\$18,388.50	Wages	CTO, CDO
Hoekman, John D	12/15/2023	\$111,735.00	Bonus	CTO, CDO
Hoekman, John D Total		\$755,911.88		
Kalb, Michael W	5/19/2023	\$7,692.16	Wages	CFO
Kalb, Michael W	6/5/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	6/20/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	7/5/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	7/20/2023	\$833.33	401k match	CFO
Kalb, Michael W	7/20/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	8/4/2023	\$833.33	401k match	CFO
Kalb, Michael W	8/4/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	8/18/2023	\$833.33	401k match	CFO
Kalb, Michael W	8/18/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	9/5/2023	\$833.33	401k match	CFO
Kalb, Michael W	9/5/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	9/20/2023	\$833.33	401k match	CFO
Kalb, Michael W	9/20/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	10/5/2023	\$833.33	401k match	CFO
Kalb, Michael W	10/5/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	10/20/2023	\$833.33	401k match	CFO
Kalb, Michael W	10/20/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	11/3/2023	\$833.33	401k match	CFO
Kalb, Michael W	11/3/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	11/20/2023	\$833.33	401k match	CFO

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 30. Payments, distributions, or withdrawals credited or given to insiders

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
Kalb, Michael W	11/20/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	12/5/2023	\$833.33	401k match	CFO
Kalb, Michael W	12/5/2023	\$20,833.33	Wages	CFO
Kalb, Michael W	12/15/2023	\$1,200.00	401k match	CFO
Kalb, Michael W	12/15/2023	\$30,000.00	Bonus	CFO
Kalb, Michael W	12/20/2023	\$833.33	401k match	CFO
Kalb, Michael W	12/20/2023	\$20,833.33	Wages	CFO
Kalb, Michael W Total		\$339,725.41		
Leaman, John H.	12/20/2022	\$18,975.00	Wages	CFO
Leaman, John H.	12/30/2022	\$39,645.00	Taxable RSU	CFO
Leaman, John H.	1/5/2023	\$18,975.00	Wages	CFO
Leaman, John H.	1/20/2023	\$18,975.00	Wages	CFO
Leaman, John H.	2/3/2023	\$18,975.00	Wages	CFO
Leaman, John H.	2/17/2023	\$18,975.00	Wages	CFO
Leaman, John H.	2/17/2023	\$100,188.00	Bonus	CFO
Leaman, John H.	3/3/2023	\$22,011.00	Wages	CFO
Leaman, John H.	3/20/2023	\$23,680.80	Wages	CFO
Leaman, John H. Total		\$280,399.80		
Paolillo, Leonard S	12/20/2022	\$175.95	401k match	CCO
Paolillo, Leonard S	12/20/2022	\$17,595.26	Wages	CCO
Paolillo, Leonard S	1/5/2023	\$175.95	401k match	CCO
Paolillo, Leonard S	1/5/2023	\$17,595.26	Wages	CCO
Paolillo, Leonard S	1/20/2023	\$175.95	401k match	CCO
Paolillo, Leonard S	1/20/2023	\$17,595.26	Wages	CCO
Paolillo, Leonard S	2/3/2023	\$175.95	401k match	CCO
Paolillo, Leonard S	2/3/2023	\$17,595.26	Wages	CCO
Paolillo, Leonard S	2/14/2023	\$10,416.00	ISO Options Granted, Amount Vested as of 1/8/24	CCO, Interim CEO
Paolillo, Leonard S	2/17/2023	\$175.95	401k match	CCO
Paolillo, Leonard S	2/17/2023	\$1,021.93	401k match	CCO
Paolillo, Leonard S	2/17/2023	\$17,595.26	Wages	CCO
Paolillo, Leonard S	2/17/2023	\$102,193.29	Bonus	CCO
Paolillo, Leonard S	3/3/2023	\$204.10	401k match	CCO
Paolillo, Leonard S	3/3/2023	\$20,410.50	Wages	CCO
Paolillo, Leonard S	3/20/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	3/20/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	4/5/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	4/5/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	4/20/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	4/20/2023	\$18,299.07	Wages	CCO

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 30. Payments, distributions, or withdrawals credited or given to insiders

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
Paolillo, Leonard S	5/5/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	5/5/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	5/19/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	5/19/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	6/5/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	6/5/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	6/20/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	6/20/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	7/5/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	7/5/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	7/20/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	7/20/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	8/4/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	8/4/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	8/18/2023	\$182.99	401k match	CCO
Paolillo, Leonard S	8/18/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	9/5/2023	\$731.96	401k match	CCO
Paolillo, Leonard S	9/5/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	9/20/2023	\$731.96	401k match	CCO
Paolillo, Leonard S	9/20/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	9/20/2023	\$65,877.00	Advanced Severance	CCO
Paolillo, Leonard S	10/5/2023	\$731.96	401k match	CCO
Paolillo, Leonard S	10/5/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	10/20/2023	\$731.96	401k match	CCO
Paolillo, Leonard S	10/20/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	11/3/2023	\$731.96	401k match	CCO
Paolillo, Leonard S	11/3/2023	\$18,299.07	Wages	CCO
Paolillo, Leonard S	11/20/2023	\$941.16	401k match	CCO, Interim
Paolillo, Leonard S	11/20/2023	\$23,528.97	Wages	CCO, Interim
Paolillo, Leonard S	12/5/2023	\$1,000.00	401k match	CCO, Interim
Paolillo, Leonard S	12/5/2023	\$25,000.00	Wages	CCO, Interim
Paolillo, Leonard S	12/15/2023	\$335,000.00	Bonus	CCO, Interim
Paolillo, Leonard S Total		\$972,906.81		
Shrewsbury, Stephen	12/20/2022	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	1/5/2023	\$707.25	401k match	CMO
Shrewsbury, Stephen	1/5/2023	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	1/20/2023	\$707.25	401k match	CMO
Shrewsbury, Stephen	1/20/2023	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	2/3/2023	\$707.25	401k match	CMO

Impel Pharmaceuticals, Inc.

Case No. 23-80016

SOFA 30. Payments, distributions, or withdrawals credited or given to insiders

Creditor's name	Dates	Total amount or value	Reasons for payment or transfer	Relationship to debtor
Shrewsbury, Stephen	2/3/2023	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	2/17/2023	\$707.25	401k match	CMO
Shrewsbury, Stephen	2/17/2023	\$4,201.07	401k match	CMO
Shrewsbury, Stephen	2/17/2023	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	2/17/2023	\$105,026.63	Bonus	CMO
Shrewsbury, Stephen	3/3/2023	\$707.25	401k match	CMO
Shrewsbury, Stephen	3/3/2023	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	3/20/2023	\$707.25	401k match	CMO
Shrewsbury, Stephen	3/20/2023	\$17,681.25	Wages	CMO
Shrewsbury, Stephen	3/31/2023	\$44,341.28	Wages/Severance	CMO
Shrewsbury, Stephen	4/20/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	5/5/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	5/19/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	6/5/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	6/20/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	7/5/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	7/20/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	8/4/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	8/18/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	9/5/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	9/20/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	10/5/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	10/20/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	11/3/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	11/20/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen	12/5/2023	\$18,555.36	Severance	CMO
Shrewsbury, Stephen Total		\$578,466.99		
Grand Total		\$3,780,746.45		